[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2026
1. Hervás Benito I, Pérez Velasco R, Vera Espallardo F, Bello Arques P, Saura Quiles A, González Cabezas P, Mateo Navarro A: [Bone scintigraphy in two cases of primary vertebral osteosarcoma in adults]. Rev Esp Med Nucl; 2001 Jun;20(4):299-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone scintigraphy in two cases of primary vertebral osteosarcoma in adults].
  • [Transliterated title] Gammagrafía ósea en dos casos de osteosarcoma vertebral primario en edad adulta.
  • The primary vertebral osteosarcoma in adults is a rare tumor which represents less than 2% of all osteosarcomas.
  • The imaging methods used to study the tumors were X-rays, CT, MRI and bone scintigraphy with 99mTc-HMDP.
  • After the pathological diagnosis, the tumors were removed surgically and the treatment was completed with chemotherapy and radiotherapy.
  • In this report the authors review the published cases of vertebral osteosarcoma, its epidemiology, clinical presentation and characteristics in the different imaging techniques.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Cervical Vertebrae / radionuclide imaging. Lumbar Vertebrae / radionuclide imaging. Osteosarcoma / radionuclide imaging
  • [MeSH-minor] Adult. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Discitis / diagnosis. Embolization, Therapeutic. Humans. Intervertebral Disc Displacement / diagnosis. Low Back Pain / etiology. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Osteoblastoma / diagnosis. Osteolysis / etiology. Osteolysis / radionuclide imaging. Radiotherapy, Adjuvant. Spinal Cord Compression / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11940418.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Carrle D, Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop; 2006 Dec;30(6):445-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current strategies of chemotherapy in osteosarcoma.
  • Osteosarcoma, the most common type of primary malignant tumour that develops in bone, can be classified into several different sub-types.
  • Since the introduction of chemotherapy into the multi-modal treatment regimen of high-grade osteosarcoma, its prognosis has impressively improved, with long-term survival being achieved in two-thirds of all patients.
  • This review summarises current chemotherapeutic treatment strategies in classical osteosarcoma and also addresses the indication for chemotherapy in more unusual types and variants.
  • It emphasises the need for treatment in specialised centres and within prospective, multi-institutional trials, amongst which EURAMOS1 and EURO-B.O.S.S are currently active in many European countries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1164 [10561175.001]
  • [Cites] Eur J Cancer. 2005 Dec;41(18):2806-11 [16290134.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):521-7 [11786582.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Chemother. 2002 Apr;14(2):198-206 [12017378.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2202-10 [12412175.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):157-63 [12509946.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):710-5 [12586810.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1574-80 [12697883.001]
  • [Cites] Pediatr Blood Cancer. 2004 Apr;42(4):295-310 [14966825.001]
  • [Cites] Expert Opin Pharmacother. 2004 Jun;5(6):1243-56 [15163270.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):92-8 [15188671.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2699-705 [7989947.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):683-4 [8636791.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):363-7 [8996163.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2095-106 [9179055.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1107-15 [9426330.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1044-54 [10091787.001]
  • [Cites] Can J Surg. 1999 Jun;42(3):190-9 [10372015.001]
  • [Cites] J R Coll Surg Edinb. 1955 Dec;1(2):79-111 [13307660.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):559-68 [15659502.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2004-11 [15774791.001]
  • [Cites] Klin Padiatr. 2005 May-Jun;217(3):176-81 [15858710.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Aug;131(8):520-6 [15918046.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2789-95 [10561354.001]
  • (PMID = 16896870.001).
  • [ISSN] 0341-2695
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC3172747
  •  go-up   go-down


3. Castro JA, Hernández M, Sierra AC, Méndez JM, Macías C CR: [Distal tibial reconstruction and ankle arthrodesis in osteosarcoma (salvage technique). A case presentation]. Acta Ortop Mex; 2007 Sep-Oct;21(5):289-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distal tibial reconstruction and ankle arthrodesis in osteosarcoma (salvage technique). A case presentation].
  • [Transliterated title] Reconstrucción de tibia distal y artrodesis de tobillo en osteosarcoma (cirugía de salvamento). Presentación de un caso.
  • Treatment of bone sarcomas is aimed in healing and secondarily rescuing the limb.
  • With the use of chemotherapy, radiation therapy, new prostheses and availability of graft, now most tumors can be resected, reducing functional deficit.
  • OBJECTIVE: To present a surgical option in management of osteosarcoma of distal tibia.
  • The patient received 11 sessions of chemotherapy.
  • The reconstruction of the distal tibia and arthrodesis with autologous graft from the fibula, heterologous graft and stabilization with transcalcaneal nail, was done in March 2005.
  • [MeSH-major] Arthrodesis / methods. Bone Neoplasms / surgery. Osteosarcoma / surgery. Tibia / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Nails. Chemotherapy, Adjuvant. Chondroblastoma / diagnosis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnostic Errors. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fibula / transplantation. Humans. Ifosfamide / administration & dosage. Internal Fixators. Male. Transplantation, Autologous

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159919.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res; 2005 Mar 1;65(5):1748-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
  • Osteosarcoma is the most common malignant bone tumor in children.
  • Osteosarcoma patients who respond poorly to chemotherapy are at a higher risk of relapse and adverse outcome.
  • Therefore, it was the aim of this study to identify prognostic factors at the time of diagnosis to characterize the genes predictive of poor survival outcome and to identify potential novel therapeutic targets.
  • Expression profiling of 30 osteosarcoma diagnostic biopsy samples, 15 with inferior necrosis following induction chemotherapy (Huvos I/II) and 15 with superior necrosis following induction chemotherapy (Huvos III/IV), was conducted using Affymetrix U95Av2 oligonucleotide microarrays.
  • Statistically significant genes were validated on a small independent cohort comprised of osteosarcoma xenograft tumor samples.
  • Additional genes involved in osteoclastogenesis and bone resorption, which were statistically different, include annexin 2, SMAD, PLA2G2A, and TGFbeta1.
  • We propose that osteosarcoma tumor-driven changes in the bone microenvironment contribute to the chemotherapy-resistant phenotype and offer testable hypotheses to potentially enhance therapeutic response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Biopsy. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / metabolism. Child. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Gene Expression Regulation, Neoplastic. Humans. Methotrexate / administration & dosage. Mice. Mice, SCID. Necrosis. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Signal Transduction. Survival Rate. Transplantation, Heterologous. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753370.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 7 R21 CA095618-02
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Botchu R, Ravikumar KJ, Sudhakar G, Meruva S, Anwar R: Osteosarcoma of rib in a seven-year-old child: a case report. Eur J Orthop Surg Traumatol; 2006 Jun;16(2):156-157
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of rib in a seven-year-old child: a case report.
  • Primary tumours of ribs are relatively uncommon in adults and are even rarer in children. (William in Am Surg June: 338-342, 1972; Eskenasy in Rev Roum Morph Embryol Physio 1:35-50, 1985) Osteosarcoma is the most common primary bone malignancy in children and young adults. (Whelan in Eur J Can 33(10):1611-1619, 1997) Very few cases of osteosacoma of the rib have been described in literature.
  • We report a 7-year-old girl with primary osteosarcoma of the rib which was managed by wide excision followed by adjuvant chemotherapy.
  • We believe our case to be the youngest with primary osteosarcoma of the rib.
  • Primary osteosarcoma of the rib should be considered in the differential diagnosis in a child with rib swelling.
  • Early diagnosis and treatment improves the outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Indian J Pediatr. 2004 Jun;71(6):543-4 [15226567.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):973-89 [9286295.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Jun;11(6):1011-6 [9237580.001]
  • [Cites] Ann Thorac Surg. 1992 Aug;54(2):226-32 [1637209.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Feb 15;28(4):E74-7 [12590223.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1611-8; discussion 1618-9 [9389923.001]
  • [Cites] Morphol Embryol (Bucur). 1985 Jan-Mar;31(1):35-50 [3157052.001]
  • (PMID = 28755109.001).
  • [ISSN] 1633-8065
  • [Journal-full-title] European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
  • [ISO-abbreviation] Eur J Orthop Surg Traumatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Keywords] NOTNLM ; Child / Osteosarcoma / Rib
  •  go-up   go-down


6. Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB: Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res; 2008 Jun;466(6):1292-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults.
  • The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [3, 5, 6, 20, 22, 35].
  • We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival.
  • We report the results of treating 53 adults (age 18-77 years) diagnosed with nonmetastatic extremity osteosarcoma or malignant fibrous histiocytoma.
  • Preoperative chemotherapy consisted of intravenous doxorubicin followed by intraarterial cisplatinum administered repetitively every 3 weeks for three to five cycles, depending on tumor response assessed by serial arteriography.
  • After resection, good responders (90% or greater necrosis) underwent treatment with the same agents and poor responders were treated with alternative agents for longer duration.
  • LEVEL OF EVIDENCE: Level III, therapeutic study.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Bone Neoplasms / drug therapy. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Histiocytoma, Malignant Fibrous / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arm Bones. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Infusions, Intravenous. Leg Bones. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Ann Oncol. 1992 Apr;3 Suppl 2:S3-6 [1622860.001]
  • [Cites] Chir Organi Mov. 1996 Sep-Dec;81(4):369-82 [9147928.001]
  • [Cites] Clin Orthop Relat Res. 1997 Apr;(337):216-25 [9137193.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):765-71 [9332684.001]
  • [Cites] Acta Oncol. 1998;37(1):41-8 [9572653.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):423-31 [8113851.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jul;165(1):135-42 [7785572.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):631-7 [10203605.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:58-61 [10429624.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):949-56 [10491520.001]
  • [Cites] J Nucl Med. 1999 Oct;40(10):1637-43 [10520703.001]
  • [Cites] Clin Orthop Relat Res. 2004 Dec;(429):286-91 [15577500.001]
  • [Cites] J Vasc Interv Radiol. 2005 Aug;16(8):1107-19 [16105923.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:128-36 [16131881.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8845-52 [16246977.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1154-61 [16421923.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):112-28 [17227995.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):118-23 [17577221.001]
  • [Cites] Tumori. 1999 Nov-Dec;85(6):458-64 [10774566.001]
  • [Cites] Clin Nucl Med. 2000 Nov;25(11):874-81 [11079583.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] J Chemother. 2001 Feb;13(1):93-9 [11233808.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):498-507 [12794015.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] JAMA. 1972 Sep 4;221(10):1132-8 [4512088.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Med Pediatr Oncol. 1978;4(2):127-32 [275532.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):248-54 [6936069.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):1-4 [6263447.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):402-7 [6571796.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1101-4 [3874932.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):194-202 [3164231.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):63-7 [2910425.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):839-42 [2916040.001]
  • [Cites] Skeletal Radiol. 1990;19(3):165-72 [2185556.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1703-10 [2208024.001]
  • [Cites] Clin Orthop Relat Res. 1991 Mar;(264):156-68 [1997230.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):489-94 [1911456.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):269-73 [1793151.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):411-5 [9010116.001]
  • (PMID = 18437502.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2384032
  •  go-up   go-down


7. Pérez Serna AG, Moreno Hoyos LF, Ramírrez Valdivia S: [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture]. Acta Ortop Mex; 2009 Nov-Dec;23(6):351-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative surgery as an alternative treatment of a knee osteosarcoma in the presence of a pathological fracture].
  • [Transliterated title] Cirugía de salvamento como alternativa en el tratamiento de osteosarcoma de rodilla ante la presencia de fractura en terreno patológico.
  • INTRODUCTION: classical osteosarcoma is defined as a very malignant spindle cell sarcoma, characterized by the production of osteoid matrix, it is the most common primary malignant bone tumor.
  • Conservative surgery is inappropriate; however, preoperative chemotherapy and a good choice of conservative treatment are an alternative.
  • MATERIAL AND METHODS: a 15-year-old male patient presented at the orthopedics service with a diagnosis of a pathological fracture in the distal third of the right femur and a tumor in the lateral aspect of the knee, with pain and limitation of gait.
  • Based on X-rays, a bone scan and a biopsy, the diagnosis of a fibroblastic osteosarcoma, an Enneking IIB lesion, was made.
  • Treatment consisted of conservative surgery with broad tumor resection involving 18 cm of the femur, resection of the vastus medialis and vastus lateralis, release of the femoral bundle, the popliteal and sciatic nerves, as well as placement of a modular stryker tumor prosthesis, with knee replacement.
  • DISCUSSION: this is a case salvage surgery to treat a pathological fracture resulting from a malignant bone tumor.
  • We think that staging is essential to select the treatment.
  • In the case presented herein a comprehensive management is fundamental to the success of conservative treatment.
  • [MeSH-major] Femoral Neoplasms / surgery. Fractures, Spontaneous. Knee Prosthesis. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Gait. Humans. Limb Salvage. Male. Quadriceps Muscle / surgery. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377001.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


8. Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ, Modrowski D: Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res; 2007 Apr 15;67(8):3708-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
  • We previously showed that syndecan-2 is involved in the control of apoptosis in cultured osteosarcoma cells.
  • These data led us to the hypothesis that syndecan-2 may play a role in the apoptotic signaling in bone tumors.
  • We immunohistochemically analyzed tissue sections from biopsies from 21 patients with well-characterized osteosarcoma.
  • These tissues expressed low levels of syndecan-2 compared with osteoblasts and osteocytes in normal bone.
  • Cultured human osteosarcoma cells also produced lower mRNA levels of syndecan-2 than normal osteoblastic cells.
  • Moreover, the presence of syndecan-2 correlated with spontaneous apoptosis in osteosarcoma tissues as assessed by detection of DNA fragmentation in situ.
  • Overexpression of syndecan-2 resulted in decreased number of migrating and invading U2OS osteosarcoma cells in Matrigel.
  • In addition, overexpression of syndecan-2 sensitized human osteosarcoma cells to chemotherapy-induced apoptosis, increasing the response to methotrexate, doxorubicin, and cisplatin.
  • Consistently, knockdown of the proteoglycan using stable transfection with a plasmid coding small interfering RNA resulted in inhibition of chemotherapy-induced apoptosis.
  • Analysis of syndecan-2 expression both in biopsies and in corresponding postchemotherapy-resected tumors, as well as in cells treated with methotrexate or doxorubicin, showed that the cytotoxic action of chemotherapy can be associated with an increase in syndecan-2.
  • These results provide support for a tumor-suppressor function for syndecan-2 and suggest that dysregulation of apoptosis may be related to abnormal syndecan-2 expression or induction in osteosarcoma.
  • Moreover, our data identify syndecan-2 as a new factor mediating the antioncogenic effect of chemotherapeutic drugs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / metabolism. Osteosarcoma / drug therapy. Osteosarcoma / metabolism. Syndecan-2 / biosynthesis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440083.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 149769-25-5 / Syndecan-2; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. El Mouedden M, Meert TF: The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. Pharmacol Biochem Behav; 2007 May;87(1):30-40
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain.
  • Chronic pain resulting from metastasis into skeleton of certain neoplastic diseases remains poorly understood and relatively resistant to analgesic treatment.
  • Opioids are the principal axis in drug therapy for this type of pain, especially at the end stage of cancer.
  • Our aim was to examine whether, fentanyl as well as morphine, two potent analgesic opioids commonly used to treat cancer pain, would inhibit pain and bone lesion-related responses in a murine model of bone cancer pain.
  • Repeated administration of equianalgesic doses of fentanyl (0.16 mg/kg s.c. once a day) and morphine (20 mg/kg s.c. once a day) initiated at day 1 (prophylactic treatment) or at day 7 (curative treatment) after tumor cell inoculation in the femoral cavity consistently decreased bone pain symptoms and tumor growth-induced bone destruction (micro-CT bone structure parameters).
  • Both fentanyl and morphine treatments resulted in clear antinociceptive properties as well as reductions in cancer cell-induced bone lesions.
  • The present results demonstrate that fentanyl, and to some lesser degree morphine, has potential benefits in the treatment and development of bone cancer pain.
  • As such, chronic administration of high doses of certain opioids like fentanyl may have clinical utility in the management of bone cancer pain.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Bone Neoplasms / complications. Bone Neoplasms / pathology. Bone and Bones / pathology. Fentanyl / therapeutic use. Morphine / therapeutic use. Osteosarcoma / complications. Osteosarcoma / pathology. Pain Measurement / drug effects. Pain, Intractable / drug therapy. Pain, Intractable / etiology
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Body Weight / drug effects. Femur / pathology. Femur / radiography. Male. Mice. Mice, Inbred C3H. Naloxone / pharmacology. Narcotic Antagonists / pharmacology. Neoplasm Transplantation. Postural Balance / drug effects. Tomography, X-Ray Computed. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. FENTANYL .
  • Hazardous Substances Data Bank. NALOXONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17521715.001).
  • [ISSN] 0091-3057
  • [Journal-full-title] Pharmacology, biochemistry, and behavior
  • [ISO-abbreviation] Pharmacol. Biochem. Behav.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Narcotic Antagonists; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; UF599785JZ / Fentanyl
  •  go-up   go-down


10. Rydzewski B, Matusiak M: [Osteosarcoma of the larynx]. Otolaryngol Pol; 2005;59(2):285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteosarcoma of the larynx].
  • [Transliterated title] Osteosarcoma krtani.
  • The authors present a case of rare laryngeal neoplasm--osteosarcoma, which generated many diagnostic and treatment difficulties.
  • No cancer nor tuberculosis was found".
  • After the physiologic consultations and with positive tuberculin test the tuberculocidal treatment was applied, but it bought no success.
  • Postoperative immunohistochemical examination was "Osteosarcoma of larynx".
  • The patient was not evaluated for radio- or chemotherapy.
  • Patient noted to chemotherapy.
  • [MeSH-major] Laryngeal Neoplasms. Osteosarcoma
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Laryngectomy. Male

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095104.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Gallaher BW, Berthold A, Klammt J, Knüpfer M, Kratzsch J, Bartsch M, Kiess W: Expression of apoptosis and cell cycle related genes in proliferating and colcemid arrested cells of divergent lineage. Cell Mol Biol (Noisy-le-grand); 2000 Feb;46(1):79-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However the requirement for tissue and cell type specificity suggests that a wide variety of mechanisms are used to achieve the same purpose.
  • Transformed human osteosarcoma cells (MG63) and non-transformed human kidney embryonal fibroblasts (293-0) were kept in culture in medium containing 10% FCS and growth arrest was induced by the addition of 50 ng/ml colcemid.
  • Colcemid treatment caused growth arrest and elevated expression of cyclin B1 protein in both cell lines.
  • Colcemid treatment did not markedly influence c-myc, p53 and p21/WAF expression in MG63 cells but did suppress c-myc and increase p21/WAF in 293-0 cells.
  • Furthermore colcemid treated MG63 cells exhibited elevated bcl-2 and bax-alpha expression while similar treatment of 293-0 cells resulted in decreased bcl-X(L) and slightly increased bax-alpha expression.
  • While growth arrest and apoptosis were induced in both MG63 and 293 cells following colcemid treatment, the differences in gene expression suggest that the mechanism by which these cells determine cell fate is quite different and may determine the sensitivity of different cell populations to anti-neoplastic drug therapy.
  • [MeSH-minor] Cell Count / drug effects. Cell Line. Cyclin B / metabolism. Cyclin B1. Cyclin-Dependent Kinase Inhibitor p21. Cyclins / genetics. Demecolcine / pharmacology. Gene Expression Regulation. Genes, bcl-2 / genetics. Genes, myc / genetics. Genes, p53 / genetics. Humans. Nucleosomes / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. RNA, Messenger / metabolism. bcl-2-Associated X Protein. bcl-X Protein

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10726974.001).
  • [ISSN] 0145-5680
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / CCNB1 protein, human; 0 / CDKN1A protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Nucleosomes; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; Z01IVE25KI / Demecolcine
  •  go-up   go-down


12. Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, Woźniak W: [Biochemical bone resorption markers in children with osteosarcoma]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):225-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biochemical bone resorption markers in children with osteosarcoma].
  • [Transliterated title] Biochemiczne wskaźniki procesu resorpcji kości u dzieci z osteosarcoma.
  • Biochemical markers of bone resorption such as the bane collagen breakdown products and specific factors associated with osteoclastogenesis are useful for monitoring the response of anticancer therapy and to assess disease progression in patients with metastatic bone disease.
  • AIM: the aim of present study was to assess bone resorption process by collagen type I crosslinked C-telopeptide and osteoprotegerin levels in children with osteosarcoma.
  • SUBJECTS AND METHODS: in serum of 20 patients (10-19 years) with osteosarcoma, bone resorption markers were determined: at diagnosis (before treatment), during preoperative and postoperative chemotherapy and after treatment.
  • Bone resorption markers were measured by immunoenzymatic ELISA assays.
  • RESULTS: mean serum concentration of collagen type I crosslinked C-telopeptide in patients at the time of diagnosis was 15206 +/- 6808 pM/L. then it decreased by 15% during preoperative chemotherapy and it increased during the postoperative chemotherapy.
  • In addition, the mean osteoprotegerin level was 3.73 +/- 0.78 pM/L at diagnosis, it increased by 12% during preoperative chemotherapy and then it decreased during the postoperative phase.
  • Patients after therapy were divided into two subgroups: with favourable and unfavourable prognosis, In patients with favourable prognosis we observed lower serum concentrations of both resorption markers in comparison to patients with poor prognosis.
  • CONCLUSIONS: bone resorption markers: may be useful for assessing bone resorption process and can be used in diagnosis and monitoring therapy of patients with osteosarcoma.
  • Higher serum concentration bone resorption markers (especially osteoprotegerin) may be related to poor prognosis.
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / metabolism. Bone Resorption / metabolism. Collagen / blood. Glycoproteins / blood. Osteosarcoma / metabolism. Peptides / blood. Receptors, Cytoplasmic and Nuclear / blood
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Child. Collagen Type I. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Osteoprotegerin. Prognosis. Receptors, Tumor Necrosis Factor. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738598.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / Glycoproteins; 0 / Osteoprotegerin; 0 / Peptides; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11B protein, human; 0 / collagen type I trimeric cross-linked peptide; 9007-34-5 / Collagen
  •  go-up   go-down


13. Michaud LB: Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm; 2010 Apr;67(7 Suppl 3):S20-30; quiz S31-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer.
  • PURPOSE: To discuss trends in breast and prostate cancer prevalence and survival; risk factors for bone loss, osteoporosis, and fractures and the approach to risk assessment in patients with these malignancies; established and investigational drug therapies for managing cancer treatment-induced bone loss and osteoporosis; and the role of health-system pharmacists in promoting bone health in patients with breast or prostate cancer.
  • SUMMARY: Breast cancer and prostate cancer are common, deadly diseases, but many survivors are alive today because of improvements in early detection and treatment over the past 10-15 years.
  • Cancer chemotherapy, corticosteroids, hormone-ablation therapy, and other common risk factors place patients with breast or prostate cancer at high risk for bone loss, osteoporosis, and fractures.
  • Most patients with breast or prostate cancer should undergo assessment of risk for bone loss and osteoporosis that involves a bone-related history and physical examination, dual-energy X-ray absorptiometry scanning, and the FRAX fracture risk assessment tool from the World Health Organization.
  • A recent National Comprehensive Cancer Network task force report on bone health in cancer care provides recommendations for considering the use of pharmacologic therapy on the basis of the results of this assessment.
  • Bisphosphonates are useful for slowing or preventing bone loss associated with hormone-ablation therapy in women with breast cancer and men with prostate cancer, although fracture data are limited in women and not available in men.
  • The usefulness of other therapies (selective estrogen receptor modulators, teriparatide, calcitonin salmon, and estrogens) is limited by adverse effects, a lack of experience with the drugs in these patient populations, or both.
  • Various drug therapies are in development for managing cancer treatment-induced bone loss and osteoporosis.
  • The agent closest to approval by the Food and Drug Administration, denosumab, has been shown to improve bone mineral density in women and men receiving hormone-ablation therapy for breast or prostate cancer, but additional data are needed to dispel safety concerns that could limit the use of this drug in these patient populations.
  • Health-system pharmacists play an important role in screening patients with a history of breast or prostate cancer for bone loss or osteoporosis, making drug therapy recommendations to address the problem, and counseling patients on modifiable risk factors for osteoporosis and proper use of drug therapies to improve bone health.
  • CONCLUSION: Health-system pharmacists can improve the detection and management of cancer treatment-induced bone loss and osteoporosis in patients receiving systemic therapy for breast or prostate cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Osteoporosis / chemically induced. Osteoporosis / drug therapy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bone Density / drug effects. Education, Continuing. Female. Fractures, Bone / etiology. Humans. Male. Middle Aged. Pharmacists. Professional Role. Risk Assessment. Risk Factors


14. Mateos González ME, López-Laso E, Garrido Colino C, Torres Valdivieso MJ, López Pérez J, Simón De Las Heras R: [Osteosarcoma and brain metastasis]. An Esp Pediatr; 2002 May;56(5):462-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteosarcoma and brain metastasis].
  • [Transliterated title] Osteosarcoma y metástasis cerebral.
  • INTRODUCTION: Since the advent of multimodal therapy, survival among patients with osteosarcoma in general and among those with aggressive tumors has improved.
  • Brain metastasis is considered to be a rare event in osteosarcoma, although recent reports suggest that the incidence of this complication may be increasing.
  • CASE REPORT: We report two girls with osteoblastic osteosarcoma of the femur with poor response to preoperative chemotherapy.
  • Both patients developed brain metastasis concurrent with or after the development of lung metastasis.
  • DISCUSSION: We advocate periodic neurologic examination and neuroradiologic screening for the early detection of brain involvement in patients whose disease recurs within 1 year of diagnosis, in those with metastasis at diagnosis and in those with a poor histologic response to preoperative chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Femoral Neoplasms / pathology. Frontal Lobe. Osteosarcoma / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12042122.001).
  • [ISSN] 0302-4342
  • [Journal-full-title] Anales españoles de pediatría
  • [ISO-abbreviation] An. Esp. Pediatr.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


15. Samardziski M, Zafiroski G, Tolevska C, Konstadinova-Kunovska S, Vasilevska V: Parosteal osteosarcoma. Bratisl Lek Listy; 2009;110(4):240-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parosteal osteosarcoma.
  • In this retrospective clinical study, 6 cases of osteosarcoma of the bone have been analyzed.
  • Five patients were with parosteal osteosarcoma and one with periosteal osteosarcoma.
  • This tumor represents 1.5% of all primary bone tumors treated at the Clinic in the 11 year period.
  • The history analysis of the patients showed misinterpreted diagnosis in 50% of the cases, with 83.3% rate of local recurrence, 33.3% of metastases and 33.3% of mortality.
  • The clinical and histopathological findings (identical with those reviewed in the literature) confirmed occurrence of two biologically different types of parosteal osteosarcoma: predominant type is originally "benign" but has a definite malignant potential, causing metastases after long symptom-free interval.
  • The other type is highly malignant from the beginning.
  • More radical surgery is recommended for the latter category of tumors, followed by chemotherapy.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma, Juxtacortical / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Female. Femoral Neoplasms / diagnosis. Humans. Humerus. Male. Tibia. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507652.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


16. Gajewska J, Ambroszkiewicz J, Rychlowska-Pruszynska M, Laskowska-Klita T: [Markers of bone formation in children with osteosarcoma]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Markers of bone formation in children with osteosarcoma].
  • [Transliterated title] Markey kościotworzenia u dzieci z osteosarcoma.
  • Among biochemical markers, which reflect bone remodeling and can be measured in blood, there are formation markers such as serum bone alkaline phosphatase (BALP) and osteocalcin (OC).
  • Formation markers are considered to be useful in diagnosis and anticancer treatment of many metastatic bone diseases, but the clinical value of these markers in primary osseous tumours such as osteosarcoma is not yet recognized.
  • AIM: The aim of this study was the investigation of BALP activity and OC level in patients with osteosarcoma during clinical treatment.
  • SUBJECTS AND METHODS: We studied 22 patients (aged 11-19 years) with osteosarcoma, at diagnosis, during preoperative and postoperative chemotherapy and at the end of treatment.
  • RESULTS: Our results indicated that both tested parameters were lower during preoperative and postoperative chemotherapy (BALP, p<0.05; OC, p<0.01,p<0.001), in patients group than in controls.
  • However we found higher value of BALP and OC also at diagnosis and during chemotherapy in same patients before occurrence of metastases.
  • Moreover, we observed markedly higher activity of BALP (5:fold) and level of OC (2-fold) in patients with progression in comparison to the group with favourable prognosis, who responded to chemotherapy.
  • CONCLUSIONS: Our studies suggest, that investigation of formation markers, especially BALP could be useful in monitoring of osteosarcoma therapy and may be a valuable indicator of the progression of this disease.
  • [MeSH-major] Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Bone Neoplasms / metabolism. Bone Regeneration. Osteocalcin / blood. Osteosarcoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Resorption. Case-Control Studies. Child. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Prognosis. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738599.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


17. Hong S, Rha S, Jeong J, Lee Y, Shin S, Shin K, Roh J: Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity. J Clin Oncol; 2009 May 20;27(15_suppl):10542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity.
  • : 10542 Background: Multimodal approach had improved outcomes of non-metastatic osteosarcoma.
  • This study was to compare outcomes between doublet (AP; doxorubicin and cisplatin) and triplet (IAP; AP and ifosfamide) neoadjuvant chemotherapy for non-meteastatic osteosarcoma of extremity in a single institute.
  • METHODS: A total of 124 osteosarcoma patients were enrolled.
  • After completion of 3 cycles of chemotherapy, patients underwent limb-salvage surgery.
  • We assessed tumor response according to pathologic tumor necrosis, and treated further adjuvant chemotherapy.
  • In IAP group, all patients had 3 more cycles of IAP chemotherapy.
  • The most frequent site and histology were distal femur and osteoblastic type.
  • In toxicity profiles, there were more hematologic toxicity in IAP group (febrile neutropenia,p<0.001; thrombocytopenia,p<0.05), while there were no statistical differences in treatment related death.
  • CONCLUSIONS: The addition of ifosfamide to doxorubicin and cisplatin in neoadjuvant chemotherapy did not show improved outcomes in this study.
  • Further trials are required to elucidate optimal neoadjuvant chemotherapy and effective salvage regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Heron DE, Gerszten K, Brufsky AM, Kurman M: The effect of chemotherapy (CT) and external beam radiotherapy (RT) on bone marrow (BM) toxicity of radionuclides in the treatment of bone metastases secondary to breast cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):796

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of chemotherapy (CT) and external beam radiotherapy (RT) on bone marrow (BM) toxicity of radionuclides in the treatment of bone metastases secondary to breast cancer.
  • : 796 Background: Bone metastases are commonly seen in patients with metastatic breast cancer.
  • Radionuclide therapy has been shown to alleviate the pain of bone metastases but may be associated with BM toxicity, particularly thrombocytopenia.
  • Because many patients with breast cancer and bone metastases also receive CT and RT, we examined the effects of these other treatments on the BM of samarium (Sm)-153-EDTMP (Quadramet®).
  • METHODS: A retrospective review of patients (pts) with breast cancer and bone metastases who had received Sm-153-EDTMP was undertaken.
  • Twenty-eight pts received 29 different chemotherapy regimens prior to treatment with Sm-153-EDTMP.
  • Pre- and post-treatment data were available for 21 courses of Sm-153-EDTMP in 20 patients who received CT and RT and for 6 courses of Sm-153-EDTMP in 5 patients who received CT alone.
  • Median time to nadir was 28 days.
  • CONCLUSIONS: Sm-153-EDTMP is well tolerated in patients with breast cancer who also receive CT and RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Longhi A, Pasini A, Baldini N, Baronio F, Pellacani A, Cicognani A, Bacci G: Height as a risk factor in osteosarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Height as a risk factor in osteosarcoma.
  • : 9042 Background: The highest incidence of osteosarcoma in dogs of large breed suggested that height can play a role in the pathogenesis of this human bone sarcoma typical of childhood and adolescence Methods: A continuous series of 962 patients (560 males and 402 females) with bone osteosarcoma treated at the same institution between 1981 and 2001 were evaluated.
  • 836 had localized disease, whereas 126 were metastatic at diagnosis.
  • The median age at diagnosis was 16.1 years (2.5-60) with a peak at 12.5 years in females (mean 18.9+/-9) and 15 years in males (mean 17.1+/-8.9).
  • All patients underwent surgery and chemotherapy.
  • The following data were retrieved: age, height and pubertal stage at diagnosis, stage of disease, site, chemotherapy protocol.
  • RESULTS: At diagnosis, a high percentage of patients of Groups 1, 2, and 3 were found to be above the 50th percentile for height of the reference population, and their mean SDS height value was significantly higher than the mean SDS Final Height value, as measured at the end of puberty (p<0.0001), both in males and females.
  • On the contrary, the height of patients with osteosarcoma in adulthood did not significantly differ from that of the reference population.
  • CONCLUSIONS: The higher incidence during the pubertal spurt, in the anatomic sites of greater growth and in taller individuals, suggests that the GH-IGF axis may play a role in the pathogenesis of osteosarcoma, in agreement with a number of previous experimental studies.
  • The finding that final height of osteosarcoma patients does not differ from that of the standard reference population may reflect the detrimental influence of aggressive multiagent chemotherapy on osteogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Aung L, Chan YH, Tan AM, Wong PS, Pho RW: Osteosarcoma in pediatric and young adult patients: The Singapore experience. J Clin Oncol; 2009 May 20;27(15_suppl):e21522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma in pediatric and young adult patients: The Singapore experience.
  • : e21522 Background: There is limited information on treatment and survival regarding these tumors in the South East Asia region.
  • We thus attempted to investigate the incidence, the treatment modalities used and the outcome of OS patients treated at the two major pediatric oncology hospitals in Singapore.
  • During the study interval, patients received neoadjuvant chemotherapy followed by definitive surgery consisting of either limb-salvage or amputation followed by adjuvant chemotherapy.
  • Chemotherapy included combination of cisplatin and doxorubicin as per the European Osteosarcoma InterGroup (EOI) and as per the Memorial Sloan-Kettering Cancer Center's (MSKCC) T12 protocols.
  • Treatment of subsequent relapses consisted of various combinations of methotrexate, ifosfamide, etoposide, other, and/or surgery.
  • The median age of diagnosis of OS was 12.4 (range, 6.6 - 17.9 years).
  • Mean survival after diagnosis of OS was 13.4 years (95% CI, 9.1 - 17.8 years).
  • The two and five-year overall survival were 56.4 % ± 86.9 % (se) and 37.5 % ± 73.9 % (se) respectively for the entire cohort.
  • The two and five-year overall survival were 77.9 % ± 100 % (se) for patients who were treated as per the MSKCC T12 protocols.
  • The two and five-year overall survival were 51.8 % ± 86.2 % (se) and 33.8 % ± 72.6 % respectively for patients who were treated as per the EOI regimen.
  • CONCLUSIONS: Survival from OS in Singapore appears to be improving since the multi-drug combination chemotherapy was introduced in 2002.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963452.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ju J, Song B, Wang Y: Impacts of microRNA-215 on cell proliferation and chemotherapy resistance in colon cancer and osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):2542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impacts of microRNA-215 on cell proliferation and chemotherapy resistance in colon cancer and osteosarcoma.
  • : 2542 Background: Translational control plays a key role in resistance to anti-cancer drug treatment.
  • METHODS: miR-215 was ectopically expressed by transient transfection in both human colon cancer cell lines and osteosarcoma cell lines.
  • The expression of miR-215 in colorectal cancer specimens and normal adjacent tissues was quantified by real time-qRT-PCR analysis.
  • RESULTS: In this study, we discovered that miR-215 down-regulates the expression of both dihydrofolate reductase (DHFR) and thymidylate synthase (TS), two of the most important chemotherapeutic targets, in human osteosarcoma U-2 OS and colon cancer HCT-116 (wt-p53) cell lines.
  • Cells with elevated miR-215 expression are more resistant to DHFR inhibitor methotrexate (MTX) or TS inhibitor Tomudex (TDX) treatment.
  • Ectopically over-expressing miR-215 triggers reduced cell proliferation and increased G2 arrest, at least in part, through the induction of p53 and p21. miR-215 transfected cells with reduced proliferating phenotype were resist to MTX or TDX treatment due to deceased cell cycle in S phase.
  • The expression of endogeneous miR-215 was highly elevated in CD133<sup>+/HI</sup> CD44<sup>+/HI</sup> colon cancer stem cells compared to CD133<sup>-</sup> CD44<sup>-</sup> colon cancer cells, suggesting that tumor stem cells may be avoiding cellular and DNA damage caused by chemotherapy with a reduced proliferating phenotype mediated by certain miRNAs such as miR-215.
  • The elevated expression of miR-215 in colon cancer stem cells with slow proliferation rate and resistance to chemotherapy further supports the role of miR-215 in cell proliferation and chemotherapy resistance.
  • CONCLUSIONS: miR-215 may have a unique potential as a novel therapeutic target and biomarker candidate in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Comandone A, Boglione A, Pochettino P, Berno E, Inguì M, Papotti M, Borasio P, Maggi G, Brach Del Prever E, Gino G: Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):e21509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas.
  • : e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • Neoadjuvant chemotherapy was performed in 4 cases (3 resected).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • Surgical resection is the fundamental therapy, but in the future the role of neoadjuvant CT will increase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ramon Y Cajal T, Mazarico J, Lopez Pousa A, Quintana M, Sala N, Altabas M, Sebio A, Robert L, Alonso C, Barnadas A: Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e21520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Controversy remains about local and adjuvant treatment.
  • METHODS: We analyzed clinicopathological variables, treatment and outcome of 33 BS patients treated at our institution from 1966 to 2007.
  • Pathology: 17 cistosarcoma phylodes (CPh), 9 angiosarcoma, 2 extraesqueletical osteosarcoma, 2 fibrosarcomas, 1 liposarcoma, 1 leiomiosarcoma, 1 malignant fibrous histiocitoma (2.9%).
  • Adjuvant chemotherapy and radiotherapy in 9 and 7 patients.
  • Radical surgery in BS should be always considered as first treatment option.
  • High-grade non-phylodes BS types may be considered for adjuvant chemotherapy although there were non-statistical differences in OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Bajpai J, Gamnagatti S, Sreenivas V, Phulia R, Sharma M, Khan SA, Rastogi S, Safaya R, Malhotra A, Bakhshi S: Role of MRI in osteosarcoma for chemotherapy response evaluation and prediction: Correlation with histological necrosis. J Clin Oncol; 2009 May 20;27(15_suppl):10540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of MRI in osteosarcoma for chemotherapy response evaluation and prediction: Correlation with histological necrosis.
  • : 10540 Background:Histologic necrosis (HN), the current gold standard for response evaluation in osteosarcoma (OS), is accessible only after neoadjuvant chemotherapy (NACT) and may get affected by confounding factors.
  • Thus, it would be useful to have surrogate markers of response evaluation and prognostication using magnetic resonance imaging (MRI) to individualize therapy.
  • METHOD: Thirty-one treatment naïve OS patients received 3 cycles of NACT followed by surgery during 2006-2008.
  • Apparent diffusion coefficient (ADC), either pre-and post NACT measurements or change following chemotherapy were not correlating well.
  • Change in shape of time intensity curve did not show significant correlation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963958.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Villarroel M, Luchtman-Jones L, Quintana J, Santana VM: Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontline treatment of localized osteosarcoma without methotrexate: Results of the St. Jude Children's Research Hospital OS99 trial.
  • : 10036 Background: Standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HD-MTX), but both agents are associated with significant toxicity and MTX administration requires complex pharmacokinetic monitoring.
  • In our previous OS91 trial, the combination of carboplatin and ifosfamide with doxorubicin and HD-MTX yielded outcomes comparable to those of cisplatin-based regimens with less long-term toxicity in localized osteosarcoma.
  • METHODS: Between 1999 and 2006, we conducted a multi-institutional trial (OS99) to evaluate the activity of carboplatin, ifosfamide, and doxorubicin without HD-MTX in newly-diagnosed patients with localized osteosarcoma.
  • Treatment comprised 12 cycles of chemotherapy given every 3 weeks: 3 consecutive cycles of carboplatin (dose targeted to AUC 8 mg/ml×min on day 1) and ifosfamide (2.65 g/m<sup>2</sup> daily for 3 days) and one cycle of doxorubicin (25 mg/m<sup>2</sup> daily for 3 days) followed by definitive surgery (week 12) and 2 additional cycles of carboplatin/ifosfamide and 3 cycles each of ifosfamide/doxorubicin and carboplatin/doxorubicin for a total of 35 weeks.
  • Forty of the 66 (60.6%) evaluable patients had good histologic response (tumor necrosis > 90%) to preoperative chemotherapy.
  • CONCLUSIONS: OS99 produced outcomes similar to cisplatin or HD-MTX containing regimens and offers an alternative treatment regimen especially for patients with renal compromise and institutions where pharmacokinetic monitoring of MTX is not available.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962584.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM: A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol; 2009 May 20;27(15_suppl):10524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
  • METHODS: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design.
  • 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens.
  • The sarcoma subtypes included: synovial sarcoma (13 pts), osteosarcoma (7 pts), leiomyosarcoma (7 pts), MFH (5 pts), Ewing/PNET (1 pt), chordoma (1 pt), others (9 pts).
  • CONCLUSIONS: Utilization of single agent reovirus for treatment of sarcoma is a novel and unique therapeutic approach to date.
  • Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963913.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • Pts characteristics: median age 41 (19-80 y), male/female 19/12; symptoms at diagnosis: dyspnoea (42%), chest and shoulder pain (39%), cough (35%), hemophtoae (13%), discomfort (10%).
  • Neoadjuvant chemotherapy was performed in 4 cases (3 resected).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • Surgical resection is the fundamental therapy, but in the future the role of neoadjuvant CT will increase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kreuter M, Bieker R, Bielack SS, Auras T, Buerger H, Gosheger G, Jurgens H, Berdel WE, Mesters RM: Prognostic relevance of increased angiogenesis in osteosarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of increased angiogenesis in osteosarcoma.
  • : 9022 Background: Osteosarcoma, the most frequent primary malignant bone tumor is a chemotherapy-sensitive tumor with survival rates reaching 50 to 80 %.
  • However, the role of angiogenesis in osteosarcoma still remains unclear.
  • METHODS: Pretherapeutic tumor biopsies of 60 patients with high grade central osteosarcoma, who were treated according to multimodal neoadjuvant protocols of the Cooperative German-Austrian-Swiss Osteosarcoma Study Group, were evaluated for intratumoral microvessel density.
  • In a subgroup analysis of 47 patients with primary high grade central osteosarcoma of the extremities without primary metastases, patients with high MVD showed significant better 5- and 10-year overall survival rates with 91 % versus 61 % for low MVD (p = 0,039).
  • A good response to chemotherapy (histological grading scale of Salzer-Kuntschik) correlated significantly with a high degree of MVD (r = 0.3; p = 0.033).
  • CONCLUSIONS: Increased angiogenesis is a prognostic indicator for better survival and response to chemotherapy in patients with osteosarcoma.
  • Thus, determination of MVD might be useful in selecting patients for further neoadjuvant treatment decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013660.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Cardoso AA, Ferreira CG, Braun R, Mendes GQ: Pharmacoeconomic analysis on high dose ifosfamide for metastatic osteosarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacoeconomic analysis on high dose ifosfamide for metastatic osteosarcoma.
  • : 9043 Background: Metastatic osteosarcoma (OS) affects a young population and has a poor prognosis with 5-year survival < 15%.
  • Ifosfamide (IFO) has shown high response rate as second-line chemotherapy (CT), but toxicity is high, as we previously reported, and overall survival is short.
  • At this end, new data may support the decision-making process.
  • METHODS: We reviewed the costs of the treatment of 27 patients with classic OS, treated with IFO for relapsed disease at INCA, from July 1999 to June 2002.
  • For cost analysis, the following parameters were included: in and outpatient visits, hospital admissions, CT (drugs, material, time and personnel), red cells and platelet transfusions, nephrologic support and blood tests.
  • The median number of cycles was 5.7; no treatment related death was observed.
  • The total cost of treatment for this cohort was US$ 234,243 with a per patient cost US$ 8,675, excluding taxes.
  • The distribution of costs was as follows: 80% related to CT costs (drugs + G-CSF + blood transfusion + antibiotics), 17% to hospital admissions and inpatient visits, 3% to other costs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013699.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Macedo CR, Cappellano AM, Noguchi DT, Martinho AP, Dias CG, Dias CG, Malheiros RC, Dutra AH, Grings M, Pires AL, Petrilli AS: Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. J Clin Oncol; 2009 May 20;27(15_suppl):10038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil.
  • : 10038 Background: We describe the experience with outpatient administration of high dose methotrexate (HDMTX) and leucovorin rescue for osteosarcoma treatment at Instituto de Oncologia Pediátrica.
  • METHODS: HDMTX (12g/m<sup>2</sup>) is administered as part of the Brazilian Osteosarcoma Treatment Group Protocol in an ambulatory basis.
  • To achieve treatment adherence, a family education program was developed.
  • Concomitantly to HD chemotherapy, low dose oral cyclophosphamide and MTX (metronomic treatment) were provided to metastatic (M) patients.
  • CONCLUSIONS: Similar to other authors' experience, outpatient administration of HDMTX lead to elevated serum levels in 42.5% of the infusions, demonstrating the importance of a well trained staff and early introduction of supportive therapies to avoid associated toxicities.
  • To a developing country, this approach helps lowering treatment costs and infection risks and increases patient adherence to treatment, with acceptable toxicities, even with the introduction of metronomic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Assi H, Le Deley MC, Missenard G, Terrier P, Le Péchoux C, Bonvalot S, Vanel D, Meric JB, Tursz T, Le Cesne A: Intensive induction chemotherapy (CT) without methotrexate (MTX) in adult patients with localized osteosarcoma (LO): Updated results of the Institut Gustave Roussy phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):9020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive induction chemotherapy (CT) without methotrexate (MTX) in adult patients with localized osteosarcoma (LO): Updated results of the Institut Gustave Roussy phase II trial.
  • Two pts developed hemopathy: 1 AML5 in a PR with concomitant relapse and 1 MDS in a GR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013658.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ferrari S, Smeland S, Bielack S, Comandone A, Dileo P, Picci P, Sundby Hall K, Eriksson M, Honegger H, Reichardt P: A European treatment protocol for bone sarcoma in patients older than 40 years. J Clin Oncol; 2009 May 20;27(15_suppl):10516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A European treatment protocol for bone sarcoma in patients older than 40 years.
  • : 10516 Background: EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) is the first prospective multicenter international study for patients 41 - 65 years old with high-grade bone sarcoma.
  • METHODS: Patients with HG Osteosarcoma (OS), HG sarcoma NOS (S), Fibrosarcoma, MFH, Leiomyosarcoma, Dedifferentiated Chondrosarcoma (DCh) were included.
  • Chemotherapy: Combinations of cisplatin/doxorubicin (CDP 100mg/m2/ADM 60mg/m2), ifosfamide/CDP(IFO 6g/m2/CDP 100mg/m2) and IFO/ADM (IFO 6g/m2/ADM 60mg/m2) were repeated three times (9 cycles).
  • One surgical-related and one chemotherapy-related death were reported.
  • CONCLUSIONS: The protocol is feasible, but the chemotherapy-related toxicity is remarkable.
  • Central location and synchronous metastases are negative prognostic factors, but 50% 3-year OS can be achieved with aggressive local and systemic treatment.
  • Osteosarcoma and high-grade sarcoma NOS benefit from chemotherapy more than patients with dedifferentiated chondrosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963653.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Perissinotto E, Fonsato V, Cavalloni G, Leone F, Mitola S, Grignani G, Surrenti N, Bussolino F, Piacibello W, Aglietta M: Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). J Clin Oncol; 2004 Jul 15;22(14_suppl):9021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1).
  • Despite intensive chemotherapy and surgery treatment, lung and bone metastases develop in about 30% of OS patients.
  • The CXCR4/SDF-1 system was shown to play a role in the homing of neoplastic cells in breast cancer as well as in rabdhomyosarcoma.
  • The adhesion and migration of SJSA cells were tested on a monolayer of bone marrow stromal cells in response to rhSDF-1.
  • We evaluated lung metastasis development in mouse model (Balb-c nu/nu) with and without monoclonal antibody anti-CXCR4 (T134) treatment.
  • CONCLUSIONS: These data suggest a possible mechanism to explain and to prevent the preferential metastatic development into bone marrow and lung tissue, where SDF-1 concentration are highest, and suggest how inhibiting CXCR4/SDF-1 axis prevents dissemination of OS cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013657.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Schwartz CL, Wexler LH, Devidas M, Goorin A, Grier H, Meyers P, Bernstein M: P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):8514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial.
  • : 8514 Background: Outcome in osteosarcoma (OS) is predicted by percent necrosis (% NEC) after pre-operative chemotherapy.
  • Efforts to improve outcome by post-operative therapeutic intensification have had limited success.
  • Historically, 70% are standard responders (SR: < 98% NEC) whose outcomes justify efforts to intensify therapy.
  • Three sequential pilots evaluated intensified therapy for SR:.
  • Good Response (GR: > 98% NEC) to preoperative chemotherapy was noted in 30.2%, with 61.2% SR and 8.7% not evaluable (surgery not performed at time stipulated by protocol).
  • CONCLUSIONS: Dexrazoxane permitted the safe escalation of cumulative doxorubicin dose without adverse effect on % NEC after pre-operative chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM: Evaluation of the safety and efficacy of pathotropic nanoparticles bearing a dominant negative cyclin G1 construct for chemoresistant osteosarcoma and other sarcomas: Phase I, II, and III studies. J Clin Oncol; 2009 May 20;27(15_suppl):10513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the safety and efficacy of pathotropic nanoparticles bearing a dominant negative cyclin G1 construct for chemoresistant osteosarcoma and other sarcomas: Phase I, II, and III studies.
  • ) Rexin-G in chemotherapy-resistant sarcoma (Phase I/II), and (2) to confirm the efficacy/safety of i.v.
  • Rexin-G in chemotherapy-resistant osteosarcoma (Phase II).
  • METHODS: Twenty patients in the Phase I/II study and 22 patients in the Phase II study received 1-2 × 10e11 cfu Rexin-G i.v., 2-3 times a week for 4 weeks.
  • Treatment was continued if the patient had < Grade 1 toxicity.
  • RESULTS: Treatment-related adverse events included chills (n=1), presyncope (n=1), photophobia (n=1) of Grade 1 severity, and fatigue (n=4) of Grade 1-2 severity.
  • The Table below shows the results for evaluable patients (n=17) in the Phase II study for osteosarcoma.
  • Kaplan-Meier analysis shows a dose-response relationship between overall survival and Rexin-G dosage in the combined Phase I/II sarcoma and Phase II osteosarcoma studies (p = 0.02; n=42).
  • CONCLUSIONS: These studies suggest that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and prolongs progression-free survival and overall survival in a dose-dependent manner in chemotherapy-resistant osteosarcoma and sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963649.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Breitfeld PP, Anderson J, Kao S, Rodeberg D, Qualman S, Wolden S, Meyer W, Children's Oncology Group: Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):8513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience.
  • : 8513 Background: Initial response to induction chemotherapy (CT) predicts FFS in osteosarcoma and Ewing sarcoma.
  • Current European studies in RMS tailor therapy based on induction response.
  • For IRS IV subjects with Group III RMS, we assessed whether reported response to induction therapy predicted FFS.
  • METHODS: We studied 453 Group III subjects who received induction CT, had response assessed at week 8 and continued with protocol therapy.
  • Induction CT was followed by radiation therapy (RT) starting after week 9.
  • Response to induction therapy was determined by radiographic measurement of tumor at weeks 0 and 8.
  • CONCLUSION: In IRS IV, response rate to induction therapy was 77% in Group III subjects but induction response had no influence on FFS overall. Table 1.
  • Response rate and FFS by induction therapy and histology [Figure: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013786.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hagleitner M, Hoogerbrugge P, Flucke U, Schreuder H, van de Luijtgaarden A, van der Graaf W, Te Loo M: Age as prognostic factor in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age as prognostic factor in osteosarcoma.
  • : 10537 Background: Osteosarcoma may occur at all ages but has a distinct age distribution from 10 to 20 years old.
  • Several retrospective studies of osteosarcoma suggest a favourable outcome for children compared to adults.
  • To evaluate whether age is indeed related to outcome, we retrospectively analyzed patients with osteosarcoma under the age of forty.
  • Furthermore, we retrospectively analyzed whether outcome of osteosarcoma in young adult patients is different when treatment took place in a pediatric or an adult oncology department.
  • METHODS: Patients with primary osteosarcoma treated in our hospital between 1978 and 2008 were included in this study.
  • Prognostic factors including histological response after neoadjuvant chemotherapy, were analyzed using Cox regression multivariate analysis.
  • RESULTS: In total, 102 patients with primary osteosarcoma were included.
  • There was no significant difference in prognostic factors, such as presence of metastasis at diagnosis.
  • Overall survival of patients aged 14-20 years was not significant different when treated in a pediatric oncology department as compared to treatment in an adult department (57.9% vs. 47.4%, p= 0.705) .
  • Osteosarcoma patients older than 20 years, showed a worse histologic response to pre-operative chemotherapy and experienced more toxicity.
  • CONCLUSIONS: Based on the results found in this study, we conclude that age is an independent prognostic factor for outcome of patients with primary osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, Pignotti E, Bacci G: Survival in high-grade osteosarcoma: Improvement in a 21-year period at a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):10515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in high-grade osteosarcoma: Improvement in a 21-year period at a single institution.
  • : 10515 Background: After the introduction of pre-operative chemotherapy in the early 1980s, treatment of osteosarcoma had not advantages from new drugs/modalities.
  • METHODS: All diagnoses of high grade osteosarcoma were included.
  • Within the subgroups, survival statistically improved in patients candidates to protocols, those who relapsed, or presented with metastatic disease at diagnosis, or had axial tumors.
  • CONCLUSIONS: Despite the lack of new drugs for osteosarcoma, survival has statistically improved, especially for those patients with the worst outcome.
  • Aggressive treatments are therefore recommended for all patients including those with poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963652.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Chugh R, Thomas D, Wathen K, Thall PF, Benjamin RS, Maki RS, Samuels BL, Keohan ML, Priebat DA, Baker LH: Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):9001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial.
  • Rules for early termination within each disease type were based on a hierarchical Bayesian probability model accounting for correlation of the responses of the 10 disease types.
  • Tissue specimens were analyzed by immunohistochemistry for c-kit, PDGFRα, PDGFR****223'3f NEEDS TO BE ADDED TO TIMES NEW ROMAN GREEK FONT****, AKT, PTEN, FKHR, and by allelic PCR analysis for PDGFRα exon 18.
  • Patients received prior chemotherapy and all had progressive disease.
  • Four month progression-free survival (PFS) rates follow: all sarcoma subtypes 18% (27/147), angiosarcoma 10% (1/10), Ewing sarcoma 0% (0/13), fibrosarcoma 29% (2/7), liposarcoma 32% (9/28), leiomyosarcoma (LMS) 20% (6/30), malignant fibrous histiocytoma 1/15 (7%), osteosarcoma 18% (3/17), peripheral nerve sheath tumor 20% (1/5), rhabdomyosarcoma 0% (0/2), synovial sarcoma 20% (4/20).
  • CONCLUSIONS: Further investigation of imatinib in the therapy of liposarcoma, LMS, and fibrosarcoma is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial.
  • : 534 Background: In vitro, D has demonstrated regulatory functions in breast cancer cells and the bone microenvironment.
  • We previously found that the baseline serum bone resorption marker, beta C-terminal telopeptides of type I collagen (B-CTx), was associated with bone-only first relapse, and that higher levels of insulin secretion as estimated by c-peptide level was associated with reduced event-free survival (EFS).
  • We hypothesized that baseline serum D might be associated with relapse of breast cancer in bone and/or other metastatic sites.
  • Stratification was by adjuvant chemotherapy, axillary lymph node status, and hormone receptor status.
  • EFS, time from randomization to recurrence, second malignancy, or death due to any cause, was the primary endpoint.
  • Recurrence-free survival (RFS), time from randomization to recurrence of the primary disease alone, was a secondary endpoint.
  • Continuous D was not associated with RFS of any relapse (p = 0.57), bone only relapse (p = 0.19), bone + other site of relapse (p = 0.73), or all bone relapse types (p = 0.66).
  • CONCLUSIONS: D was not associated with EFS or RFS in postmenopausal breast cancer patients in this well controlled hormonal therapy study, a result consistent with some, but not all, studies of this issue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Park DM, Prevedello DM, Gardner P, Lee D, Henry S, Snyderman C, Carrau R, Horbinski C, Hamilton RL, Kassam AB: Clival chordoma molecular subtypes and clinical behavior. J Clin Oncol; 2009 May 20;27(15_suppl):10538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10538 Background: Chordoma is a primary bone cancer of the axial skeleton with predilection for local invasion.
  • Primary treatment modalities consist of surgery and radiation therapy with limited role for chemotherapy.
  • Because patients with chordoma exhibit heterogeneous clinical history and response to therapy, we investigated potential markers predictive of clinical behavior.
  • The prospective nature of this study in concert with assessment of residual disease after surgery may allow for identification of distinct subpopulations of patients at greater risk of disease recurrence for consideration of adjuvant therapy.
  • The correlative in vitro study will provide an opportunity to evaluate targeted therapies customized to individual molecular subgroups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kudawara I, Ieguchi M, Aoki Y, Naka N, Araki N, Nakanishi H, Matsumine A, Myoui A, Ueda T, Yoshikawa H: Neoadjuvant chemotherapy with high-dose ifosfamide, doxorubicin and cisplatin in nonmetastatic osteosarcoma of the extremity. J Clin Oncol; 2004 Jul 15;22(14_suppl):9039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with high-dose ifosfamide, doxorubicin and cisplatin in nonmetastatic osteosarcoma of the extremity.
  • : 9039 Background: Doxorubicin (DOX), cisplatin (CDDP) and methotrexate (MTX) are active agents for the treatment of osteosarcoma (OS).
  • Neoadjuvant chemotherapy including these multi-agents has been established.
  • However, ifosfamide (IFM) is mainly used in poor responders to adjuvant chemotherapy.
  • Local wide excision was scheduled after 4 courses of chemotherapy.
  • All pts received limb-saving operations: prosthetic replacement in 21, resection in 1 and intraoperative extracorporeal autogenous irradiated bone grafts in 4.
  • Two cycles of postoperative chemotherapy consisted of DOX + CDDP, IFM and HD-MTX (10-12 g/m2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Park B, Park H, Min H, Kang H, Im H, Kim S: Prediction of tumor necrosis fraction using combined volumetric and metabolic indices derived from FDG-PET/CT in osteosarcoma patients receiving neoadjuvant chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):10539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of tumor necrosis fraction using combined volumetric and metabolic indices derived from FDG-PET/CT in osteosarcoma patients receiving neoadjuvant chemotherapy.
  • : 10539 Background: Maximum standardized uptake values (mSUV) might not reliably reflect the chemotherapy response in osteosarcoma especially when treatment response within tumors is heterogenous.
  • The purpose of this study was to compare the usefulnesses of various FDG PET/CT indices for predicting tumor response to neoadjuvant chemotherapy and to identify the most appropriate one in osteosarcoma.
  • METHODS: Thirteen patients with primary osteosarcoma (age 14±2.9 yrs, ranged 10-19 yrs) that had undergone FDG PET/CT scans before and after neoadjuvant chemotherapy were enrolled.
  • Histopathologic necrosis fractions were compared with the above-mentioned PET/CT parameters and their pre- to post-treatment ratios (MTV ratio, rMTV; mSUV ratio, rSUV; TLG ratio, rTLG).
  • rMTV and rTLG values were found to be correlated with histopathologic necrosis fractions (R<sup>2</sup>=0.45-0.65, p<0.05), whereas, mSUV and MR image volumes (MRV), both before and after treatment, rSUV values, and rMRV values were not.
  • Five patients were classified as responders and 8 as poor-responders to neoadjuvant chemotherapy defined as those with chemotherapy-induced necrosis fractions of ≥90% and <90%, respectively.
  • CONCLUSIONS: In our osteosarcoma patient population, TLG and MTV, which represent combined metabolic and volumetric indices, were found to predict tumor response better than pre- or post-treatment mSUV or rSUV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Spunt SL, Harper JA, Krasin MJ, Billups CA, Rodriguez-Galindo C: Ewing sarcoma family tumors (ESFT) as second malignant neoplasms (SMN) following treatment of a primary malignant neoplasm (PMN) during childhood. J Clin Oncol; 2004 Jul 15;22(14_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing sarcoma family tumors (ESFT) as second malignant neoplasms (SMN) following treatment of a primary malignant neoplasm (PMN) during childhood.
  • Demographic data, diagnostic and treatment information for both the PMN and SMN, and outcome data were recorded.
  • The median age at diagnosis of PMN was 4.2 years (range, 0.8-12.5 years), and of ESFT was 13.4 years (range, 4.9-22.0 years).
  • Six patients received chemotherapy for treatment of the PMN including alkylating agents (n=3), anthracyclines (n=6), and etoposide (n=1).
  • Four also received radiotherapy (RT) for the PMN (dose range, 10.8-48 Gy, median 30 Gy).
  • Four patients have died: 3 due to progressive ESFT and 1 due to a third malignancy (osteosarcoma arising within the RT field used to treat the ESFT).
  • CONCLUSIONS: The proportion of ESFT as a SMN following treatment of childhood cancer is similar to the proportion of ESFT as a PMN in childhood.
  • Patients with retinoblastoma may be at higher risk than other childhood cancer survivors for secondary ESFT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013834.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Tettoni K, Provenzi M, Fossati Bellani F, Carli M: Vinorelbine and low dose cyclophosphamide in pediatric sarcoma. A pilot study for the future European rhabdomyosarcoma protocol. J Clin Oncol; 2004 Jul 15;22(14_suppl):8540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer 2002; 94: 3263) on the activity of vinorelbine (VNB) in rhabdomyosarcoma (RMS), we report the results of a pilot study aimed to define the dose of VNB in combination with low dose continuous oral cyclophosphamide (CTX) in patients with refractory or recurrent sarcomas.
  • The study was performed in the view of utilizing this treatment as maintenance therapy in the future European protocol for high risk RMS patients.
  • There was a median of 2 prior regimens (range 1-4); 5 patients previously received high dose chemotherapy with PBSC rescue and 12 prior radiotherapy.
  • Among 5 patients treated at dose level 4 (VNB 30 mg/m<sup>2</sup>) 2 dose limiting toxicities (grade 4 neutropenia) were observed in the first 2 cycles therefore a decision was made to enter 3 more patients at dose level 3.
  • Four patients were still on treatment after 5-10 cycles.
  • Partial responses were observed in 7/17 assessable patients: 3/8 RMS (2 embryonal, 1 alveolar), 1/1 clear cell sarcoma, 1/2 synovial sarcoma, 1/2 desmoplastic small round cell tumor, 1/1 osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013816.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hester AL, Sweeney TA, Hudson MM, Billups CA, Krasin MJ, Spunt SL: Late effects following treatment for female pelvic rhabdomyosarcoma (RMS). J Clin Oncol; 2004 Jul 15;22(14_suppl):8547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects following treatment for female pelvic rhabdomyosarcoma (RMS).
  • : 8547 Background Most girls treated for RMS of the pelvic region are cured, but the effects of this treatment on long term health status are poorly documented.
  • Late effects occurring beyond 5 years from diagnosis were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
  • Results Among the 26 patients studied, the median age at diagnosis of RMS was 3.4 years (range, 0.2-17.2 years).
  • All patients received chemotherapy, which in some cases included an alkylating agent (n=23), doxorubicin (n=16), or etoposide (n=2).
  • Radiotherapy was administered to 22 patients (dose range 16-60.5 Gy, median 46 Gy).
  • Doxorubicin cardiomyopathy and secondary osteosarcoma were responsible for 2 deaths.
  • Surgical intervention for treatment of late complications was required in fourteen patients (54%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Pallotta MG, Specterman S, Gioseffi H, Lopez Lincuez ME, Beguelin GZ, Lastiri JM, Varela MS, Makiya M, Dibar E, Muscolo DL: Tumor size as prognostic factor in osteosarcomas. J Clin Oncol; 2004 Jul 15;22(14_suppl):9061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9061 Background: Multidisciplinary treatment of osteosarcoma has achieved overall survival greater than 70%.
  • In order to assess the relation between tumor size and prognosis in high-grade osteosarcoma, we performed the following analysis.
  • METHODS: Retrospectively, tumor volume was determined pre and post chemotherapy in 40 patients with histological diagnosis of high-grade osteosarcoma stage IIb.
  • All of them received neo-adjuvant chemotherapy (ifosfamide + doxorrubicin + high dose methotrexate).
  • Tumor volume pre chemotherapy greater than >1500 cm3 (MRI) was the variable most predictor of mortality (p=0.02).
  • Intensification of radiological calcification, pathological fracture and changes in size pre and post chemotherapy did not have prognostic value.
  • CONCLUSIONS: tumor measurement at diagnosis can distinguish high-risk populations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Pavoni-Ferreira PC, Petrilli AS, Alves MT, Jesus-Garcia Filho R, Toledo SR: Angiogenic biomaker study in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic biomaker study in osteosarcoma.
  • : e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.
  • METHODS: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR.
  • Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.
  • RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.
  • In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ayan I, Kebudi R, Ozger H, Yaman Agaoglu F, Gorgun O, Bilgic B, Eralp L, Dizdar Y, Darendeliler E: Childhood osteosarcoma: Evaluation of 94 cases. A single institution study. J Clin Oncol; 2009 May 20;27(15_suppl):10040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood osteosarcoma: Evaluation of 94 cases. A single institution study.
  • : 10040 Background: Osteosarcoma is the most frequent bone tumor in children and adolescents.
  • The aim of this study is to evaluate the demographic characteristics, therapy, and long term outcome of children with osteosarcoma in a single institution.
  • METHODS: Between January 1990 and December 2006, 94 children (53 male, 41 female) with a median age of 13 (5-16) years and a histopathologic diagnosis of osteosarcoma were treated with an institutional chemotherapy regimen comprising of 6 courses (3 pre-, 3 postoperatively) of epirubicin (90 mg/m2), cisplatin(100 mg/m2), and ifosfamide(2 g/m2 × 3 days) every 3 weeks.
  • RESULTS: The median follow-up time was 36 (2-219) months.
  • 68 patients were alive at the time of analysis.
  • 10 year OS for 18 patients (11 metastatic at diagnosis) who progressed during preoperative chemotherapy was 13 % vs. 75 % for those who didnot have progressive disease (p< 0.001).
  • The rate of histologically good response to preoperative chemotherapy was 64.5 %.
  • CONCLUSIONS: The presence of metastases at diagnosis was the most significant characteristic influencing outcome.
  • Our results demonstrate that the combination of epirubicin, cisplatin, and ifosfamide is an active and reasonably well-tolerated regimen for childhood osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Tap WD, Eilber FR, Rosen G, Eckardt J, Schwartz A, Federman N, Eilber FC: Long-term follow-up (&gt;20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up (>20 years) for one of the original randomized prospective trials evaluating adjuvant chemotherapy in patients with high-grade operable osteosarcoma.
  • : 10514 Background: Neoadjuvant and adjuvant chemotherapy is now standard practice for patients who present with localized osteosarcoma.
  • We present the long-term follow-up (>20years) for one of the original prospective randomized trials that compared adjuvant chemotherapy to no treatment in patients with high-grade operable osteosarcoma.
  • During this time, 59 patients with high-grade, operable, non-metastatic osteosarcoma were randomized to receive adjuvant chemotherapy (MSKCC T-10B protocol)(N=32; 24 men, 8 women, median age 15 yrs) vs. expectant management (N=27; 20 men, 7 women, median age 18 yrs).
  • At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free (55% vs. 20%, p<.01) and overall survival (80% vs. 48%, p<.01) for those who received immediate adjuvant chemotherapy.
  • Upon recurrence, patients in the T-10B arm received salvage chemotherapy with doxorubicin hydrochloride and cisplatin while those in the expectant arm received the T-10B protocol.
  • RESULTS: Median follow-up time for survivors was 24 years.
  • 18 patients in the adjuvant chemotherapy arm died of disease (DOD) while 14 have no evidence of disease (NED).
  • The 5, 10, and 20 year disease specific survival (DSS) for the treatment arm (47%, 43%, 43% respectfully) was significantly better than that of the control arm (30%, 26%, 17% respectfully) (p=0.0254).
  • CONCLUSIONS: Early administration of chemotherapy in patients with high-grade operable osteosarcoma provides a significant survival benefit that is maintained with long-term (>20 years) follow-up.
  • These results support the idea that early systemic treatment offers the best opportunity to cure patients with this high-risk malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Jaffe N: Pediatric osteosarcoma pneumonectomy for pulmonary metastases: Is it justified? J Clin Oncol; 2004 Jul 15;22(14_suppl):8565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric osteosarcoma pneumonectomy for pulmonary metastases: Is it justified?
  • Interval from diagnosis to detection of PM ranged from 1.5 to 2 yrs.
  • 1) Despite responses, all PM could not be eradicated with chemotherapy;.
  • After CPN additional chemotherapy administered.
  • Four pts were also treated with radiation therapy (45-50 Gy) to sites of suspected residual microscopic disease with methotrexate to potentiate radiotherapeutic effect.
  • Important indications appear to be inability to eradicate PM by chemotherapy and inability to perform wedge resection or lobectomy.
  • 3.2-5 yrs from diagnosis, was probably the major eligibility criterion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013873.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Landriscina M, Costantino E, Maddalena F, Piscazzi A, Fersini A, Calise S, Esposito F: TRAP1, a novel antiapoptotic gene responsible for multidrug resistance in human colorectal carcinoma cells. J Clin Oncol; 2009 May 20;27(15_suppl):2541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, novel TRAP1 antagonists cause sudden collapse of mitochondrial function and selective tumor cell death, suggesting that this pathway may represent a novel molecular target to improve anticancer therapy.
  • Furthermore, we recently observed that TRAP1 is significantly up-regulated in osteosarcoma cells adapted to growth in mild oxidizing conditions and this correlates with a phenotype more resistant to H<sub>2</sub>O<sub>2</sub>-induced DNA damage and apoptosis.
  • This evidence prompted us to investigate the role of TRAP1 as being responsible for multi-drug resistance in human colorectal cancer.
  • Interestingly, HT-29 colorectal carcinoma and Saos-2 osteosarcoma cells transfected with TRAP1 gene exhibited a phenotype resistant to 5-fluorouracil-, oxaliplatin- and irinotecan-induced apoptosis, evaluated by MTT incorporation analysis and annexin V staining.
  • Consistently, the transfection of a dominant negative N-terminal deletion mutant of TRAP1 as well as the inhibition of TRAP1 activity by the TRAP1 ATPase antagonist, shepherdin, increased the sensitivity to apoptosis induced by 5-fluorouracil, oxaliplatin and irinotecan in wild type HT-29 colorectal carcinoma cells and in HT-29 cells resistant to the single agents.
  • Thus, targeting TRAP1 may represent a novel strategy to improve the efficacy of anticancer agents in colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pourtsidis AG, Doganis D, Baka M, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Kosmidis S, Synodinou M, Strantzia C, Kosmidis H: Successful treatment with minimal chemotherapy followed by low-dose involved field radiotherapy in children with Hodgkin's disease: A 20-year experience in a single institution in Greece. J Clin Oncol; 2009 May 20;27(15_suppl):10052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with minimal chemotherapy followed by low-dose involved field radiotherapy in children with Hodgkin's disease: A 20-year experience in a single institution in Greece.
  • The purpose of our retrospective study was to report the outcome and prognostic factors of patients (pts) less than 15 years of age with HD treated with chemotherapy (CT) followed by low dose radiation from 1987 to 2006.
  • METHODS: We studied 58 children analyzing the following data: age, sex, stage, histology, therapy correlating these with the outcome of pts.
  • Among 35 boys and 23 girls, age at diagnosis 4.5 - 15 years (median 12), all aged 7 years or less were boys (8/58).
  • All pts had a good response (more than a 70% reduction) after initial CT and received 20 Gy of RT to initially involved fields.
  • Chemo- and radio-therapy were well tolerated.
  • All received salvage treatment in combination with high dose CT and autologous stem-cell transplantation (SCT).
  • Second (thyroid cancer) plus third malignancy in one (osteosarcoma) was detected in 3 pts and all are alive.
  • CONCLUSIONS: In conclusion combined-modality therapy remains the standard of care for children with HD.
  • However, there may be a significant number who can be cured with chemotherapy alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Biron P, Rolland F, Thyss A, Baranzelli MC, Rios M, Roché H, Bui B, Perol D, Blay JY, French Sarcoma group: OSAD 93: A multicentric prospective phase II study of preoperative high dose Ifosfamide and CDDP in adult patients with non metastatic osteosarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):9019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OSAD 93: A multicentric prospective phase II study of preoperative high dose Ifosfamide and CDDP in adult patients with non metastatic osteosarcoma.
  • : 9019 Objectives: Based on a previous monocentric phase II trial with neoadjuvant ifosfamide CDDP based regimen in adults, a multicentric phase II study of neoadjuvant chemotherapy for osteosarcoma of patients over 16 years was initiated in 1993 in the French Sarcoma Group.
  • METHODS: Four preoperative courses of ifosfamide 9g/m2 in 3 days and CDDP 100mg/m2 on day 4 (SHOC) were given, followed by local treatment.
  • Post operative chemotherapy was adapted according to pathological response, doxorubicin (60mg/m2) being added (HOCA regimen) in patients with tumors >10% of viable tumor cells.
  • Respectively 13%, 19%, 24%, 32% and 12% of patients had grade 4, 3, 2, 1, and non evaluable pathological response to preoperative chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013673.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. van Schie R, Hagleitner M, Hoogerbrugge P, Flucke U, Schreuder H, Te Loo M: Overall survival trends in pediatric osteosarcoma patients over the past three decades. J Clin Oncol; 2009 May 20;27(15_suppl):10041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival trends in pediatric osteosarcoma patients over the past three decades.
  • : 10041 Background: In the late seventies, the combination of chemotherapy and surgery, significantly improved survival of osteosarcoma patients.
  • However, the chemotherapeutic drugs used for treatment of osteosarcoma patients has not significantly changed since then although surgery clearly improved further and adjuvant chemotherapy have been added.
  • In this study, we retrospectively evaluated, whether after the introduction of neoadjuvant chemotherapy in the late seventies, further improvement in outcome of pediatric osteosarcoma patients was achieved.
  • METHODS: Since 1978 and 2008, 54 previously untreated pediatric patients with osteosarcoma were enrolled in six consecutive regimens of different agents and intensity.
  • The main difference between the treatment protocols is the addition of either methothrexate or ifosfamide.
  • Overall survival (OS) and event free survival (EFS) in relationship to the different treatment regimens was calculated using the Kaplan-Meier method.
  • Of all treatment regimens used, OS was the highest in patients treated with cisplatin, doxorubicin, and methotrexate (OS after 5 year 70%).
  • Multivariate analysis showed that EFS and OS significantly correlated with the histological response but not with one of the treatment regimens used.
  • CONCLUSIONS: No significant improvement in overall survival has been accomplished in pediatric osteosarcoma patients during the past thirty years.
  • Histological response after neoadjuvant chemotherapy was the most important prognostic factor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962467.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Guo W, Yang RL, Tang XD, Tang S, Li DS, Yang Y: [Neoadjuvant chemotherapy for osteosarcoma]. Zhonghua Yi Xue Za Zhi; 2004 Jul 17;84(14):1186-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy for osteosarcoma].
  • OBJECTIVE: To summarize the experience in neoadjuvant chemotherapy for osteosarcoma.
  • METHODS: Between July 1996 and December 2002 113 patients, 65 males and 48 females, aged 7 approximately 31, with osteosarcoma located in pelvis (n = 2), sacrum (n = 1), proximal femur (n = 6), shaft of femur (n = 4), distal femur (n = 49), proximal tibia (n = 37), shaft of tibia (n = 2), distal tibia (n = 1), fibula (n = 3), scapula (n = 1), clavicle (n = 1), or proximal humerus, (n = 7) without metastasis, 7 of which being at the Ennecking stage of IIA and 106 of which being at the stage of IIB, underwent 2 cycles of chemotherapy with high dose methotrexate (MTX) preoperatively and then operation.
  • If poor response was observed after the first cycle of chemotherapy MTX was abandoned and operation was performed immediately.
  • Twenty-two patients underwent reimplantation of devitalized tumor bone and 80 patients underwent prosthetic replacement.
  • At least 3 cycles of chemotherapy were given postoperatively for all patients.
  • RESULTS: Sixty patients showed excellent response to the preoperative chemotherapy, 35 showed good response, and 18 showed poor response.
  • Relapse of tumor was found in 12 out of the 22 patients (55%) receiving reimplantation of devitalized tumor bone and in 5 out of the 60 patients (8.3%) receiving prosthetic replacement.
  • CONCLUSION: The neoadjuvant chemotherapy protocol with the second-line drugs such as ifosfamide and paclitaxel used to the patients responding poorly to MTX is more effective than the older protocol.
  • Local arterial chemotherapy is feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / surgery. Humans. Ifosfamide / administration & dosage. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15387981.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


57. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • We report the 9th case of a gastrointestinal metastasis of osteosarcoma reported thus far, and only the second one arising in the duodenum.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Longhi A, Macchiagodena M, Vitali G, Bacci G: Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol; 2003 Apr;25(4):292-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
  • PURPOSE: To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents.
  • PATIENTS AND METHODS: Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities.
  • Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols.
  • Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy.
  • The median age of these patients at the time of chemotherapy was 17 years (range 10-42), the median age at the time of the interview was 27 years (range 19-53), and the median follow-up from the end of chemotherapy was 9 years (range 4-17).
  • It appears that pubertal maturation is not affected by chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Chemotherapy, Adjuvant. Ifosfamide / adverse effects. Neoadjuvant Therapy. Oligospermia / chemically induced. Osteosarcoma / drug therapy
  • [MeSH-minor] Abnormalities, Drug-Induced / epidemiology. Adolescent. Adult. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Follow-Up Studies. Humans. Incidence. Infant, Newborn. Italy / epidemiology. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Puberty. Semen Preservation. Sperm Count. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12679642.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Berend KR, Pietrobon R, Moore JO, Dibernardo L, Harrelson JM, Scully SP: Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol; 2001 Nov;78(3):162-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
  • BACKGROUND AND OBJECTIVES: Osteosarcoma is a primary malignancy of bone.
  • Current therapy includes neoadjuvant chemotherapy, surgery, and postoperative (adjuvant) chemotherapy.
  • Prolonged treatment with chemotherapeutic agents may place patients at increased risk for complications including secondary malignancy.
  • The authors have had promising results with neoadjuvant therapy and surgery alone in the treatment of osteosarcoma.
  • This study retrospectively examines neoadjuvant therapy and surgery alone for the treatment of primary osteosarcoma of bone with no evidence of distant metastases.
  • METHODS: Fifty-four patients, with localized osteosarcoma of bone received neoadjuvant therapy followed by definitive surgical resection.
  • Thirty-five patients received chemotherapy after surgery (adjuvant group) and nineteen patients were followed without postoperative chemotherapy (no adjuvant group).
  • Kaplan-Meier analysis revealed the use of postoperative chemotherapy was not a predictor of improved outcome.
  • Four patients in the adjuvant therapy group died of secondary malignancy compared with none of the no adjuvant therapy group.
  • CONCLUSIONS: The use of adjuvant chemotherapy in the treatment of localized osteosarcoma of bone did not increase survival after neoadjuvant therapy and definitive surgical therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Osteosarcoma / drug therapy. Osteosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11745799.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Lumbreras R, Castro A, Val S, Modrego FJ, Bello ML: [Salvage surgery treatment in osteosarcoma of the fibula with seventeen years survival]. Rev Fac Cien Med Univ Nac Cordoba; 2007;64(1):38-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salvage surgery treatment in osteosarcoma of the fibula with seventeen years survival].
  • [Transliterated title] Cirugía de salvación del miembro en el tratamiento de osteosarcoma de peroné con supervivencia a los diecisiete años.
  • INTRODUCTION: Osteosarcoma is the most frequent primary bony tumor with two picks of incidence, one around the 15 years (adolescents) and another in old people.
  • It was diagnosed by radiological studies and biopsy of located osteosarcoma with infiltration of cortical and periostium and extension toward fibula epiphysis.
  • After preoperatory chemotherapy she was carried out tumoral resection with margins of 5 cm. following approaches of Enneking (surgery of salvation of the member).
  • Several cycles of chemotherapy were completed after surgery.
  • DISCUSSION: Traditionally in the treatment of the located osteosarcoma you proceeded to the radical amputation for norm.
  • At the moment due to the advances of the surgical and diagnostic techniques (able to detect precociously the local and distant dissemination of the tumor) it is possible to make other therapeutic modalities that preserve the member until in 90% of the patients.
  • Thanks to the use of the chemotherapy the rate of survival nowadays approaches to 70% in those cases diagnosed previously to the metastasis appearance.
  • At the moment in those cases in which the illness is located, the tumoral size is reduced and have a good answer to the preoperatroy chemotherapy, it is more advisable to opt for a surgery of salvation of the limb making a wise resection at distance of the margins of the tumor and accompanying it of cycles of combined chemotherapy.
  • [MeSH-major] Bone Neoplasms / surgery. Fibula / surgery. Limb Salvage. Osteosarcoma / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426095.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


61. Khanna C: Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep; 2008 Jul;10(4):350-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel targets with potential therapeutic applications in osteosarcoma.
  • For patients with osteosarcoma, the development of metastases, often to the lungs, is the most common cause of death.
  • Further improvements in outcome are not likely to come from intensification of cytotoxic chemotherapy; as such, new targets for treatment are needed.
  • A view toward such targets in osteosarcoma may be constructed based on three common clinical features of the disease.
  • These include the origin of osteosarcoma in the bone or primitive mesenchymal cells, the predictable process of metastatic progression characterized by this disease, and the development of metastatic lesions almost exclusively in the lung.
  • This review summarizes novel targets under evaluation for the treatment of osteosarcoma based on these three features of the disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Humans. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):633-8 [18235123.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):147-56 [18202698.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(11):1725-31 [9470825.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2004-11 [15774791.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Dec;64(3):198-207 [17855108.001]
  • [Cites] Nat Rev Drug Discov. 2007 Sep;6(9):734-45 [17690708.001]
  • [Cites] Endocr Dev. 2005;9:11-6 [15879684.001]
  • [Cites] Curr Med Chem. 2007;14(13):1381-7 [17584050.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2293-301 [15347599.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2013-5 [15341972.001]
  • [Cites] Curr Pharm Des. 2004;10(21):2577-92 [15320746.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2406-11 [15781656.001]
  • [Cites] Curr Oncol Rep. 2007 Jul;9(4):316-22 [17588357.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7243-6 [18094402.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Sep;16(9):1459-65 [17714031.001]
  • [Cites] Life Sci. 2005 Mar 18;76(18):2091-101 [15826876.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5442-53 [14654523.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3641-8 [9817286.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2406-12 [12114446.001]
  • [Cites] Stem Cells Dev. 2007 Feb;16(1):7-23 [17348802.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):370-80 [14567994.001]
  • [Cites] Curr Med Chem. 2007;14(20):2126-35 [17691952.001]
  • [Cites] Pediatr Blood Cancer. 2008 May;50(5):976-82 [18213710.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Nov;179(1):52-61 [17981215.001]
  • [Cites] Science. 2004 Jul 9;305(5681):200-5 [15247469.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7 [17448875.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):1-11 [17208533.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Feb;42(2):158-63 [15540165.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2047-53 [15026342.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6247-51 [17975134.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3263-70 [18089720.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):541-9 [17180711.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):421-30 [14524531.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):1-26 [15922853.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85 [16831079.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):179-88 [15455381.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1625-9 [17363512.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4666-73 [16000559.001]
  • [Cites] Ann N Y Acad Sci. 2007 Oct;1113:202-16 [17513464.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):316-25 [17607709.001]
  • [Cites] Clin Exp Metastasis. 2008;25(3):201-11 [18071913.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1325-44 [15375775.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1935-44 [18339875.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1190-7 [18260118.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Jun;19(3):573-90, viii [15939198.001]
  • [Cites] J Cell Biochem. 2007 Dec 1;102(5):1095-102 [17955492.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):603-6 [17256836.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer Cell Int. 2007 Sep 10;7:14 [17845729.001]
  • [Cites] Curr Pharm Biotechnol. 2008 Feb;9(1):2-8 [18289051.001]
  • [Cites] Oncogene. 2008 Jan 24;27(5):684-93 [17684486.001]
  • [Cites] Biochem J. 2008 Mar 15;410(3):439-53 [18290764.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1607-15 [12070308.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1209-19 [8863670.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):813-9 [17265525.001]
  • [Cites] Med Hypotheses. 2008;70(2):281-6 [17683874.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1053-64 [17016635.001]
  • [Cites] Cancer Invest. 2007 Dec;25(8):785-94 [18058475.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7444-55 [17189418.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):341-6 [17545797.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2800-8 [17363602.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • (PMID = 18778562.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 69
  •  go-up   go-down


62. Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, Paglierani M, Brandi ML, Franchi A: Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):70-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in osteosarcoma of bone.
  • In addition, we examined the effects of the specific COX-2 inhibitor Celecoxib on the growth of the human osteosarcoma cell line SaOS-2.
  • In addition, low COX-2 expression was always associated with a good response to chemotherapy (5 out of 5 cases), whereas moderate or diffuse COX-2 expression was associated with a good response in 11 out of 20 cases (55%) (P = 0.12, Fisher exact test).
  • In SaOS-2 osteosarcoma cells, which express COX-2, treatment with Celecoxib determined inhibition of cell proliferation and induction of apoptosis.
  • These results indicate that COX-2 is expressed at high levels in high grade osteosarcomas and support the use of COX-2 inhibitors to improve both the tumor response to chemotherapy and the outcome of osteosarcoma patients.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536311.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


63. del Prever AB, Fagioli F, Berta M, Bertoni F, Ferrari S, Mercuri M: Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only. J Pediatr Hematol Oncol; 2005 Jan;27(1):42-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
  • A boy, age 2 years 10 months, with high-grade malignant osteosarcoma of the fifth lumbar vertebra with secondary bilateral pulmonary lesions and bone metastasis at the fifth thoracic vertebra is described.
  • The primary site of disease was inoperable and the patient was treated with chemotherapy only.
  • At present, 83 months from diagnosis and 64 from the end of therapy, he is in very good general condition.
  • Although a surgical approach on the primary and secondary sites is fundamental, this case may be considered an indication of the efficacy of aggressive chemotherapy in treating osteosarcoma.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Lumbar Vertebrae / pathology. Osteosarcoma / drug therapy. Osteosarcoma / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Carboplatin / administration & dosage. Child, Preschool. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Thoracic Vertebrae / pathology. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654278.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Liu YS, Li DF, Liu SB, Cui Q: [Intraarterial neoadjuvant chemotherapy for extremity osteosarcoma]. Zhonghua Yi Xue Za Zhi; 2009 Nov 10;89(41):2915-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraarterial neoadjuvant chemotherapy for extremity osteosarcoma].
  • OBJECTIVE: To summarize the experiences in intraarterial neoadjuvant chemotherapy for extremity osteosarcoma.
  • METHODS: Between January 2002 and December 2007, 111 patients with stage IIB extremity osteosarcoma received preoperative intraarterial chemotherapy after placing chemotherapy pump subcutaneously, en bloc resection and postoperative adjuvant chemotherapy.
  • The time from symptom onset to hospitalization varied from several days to 6 months.
  • The induction chemotherapy regimen included epirubicin [50 - 70 mg/m(2) by 4-hour intraarterial infusion/day for 3 days] and epirubicin plus adriamycin [100 - 120 mg/m(2) by 2-hour intraarterial infusion/day for 3 days] repetitively every 2 - 3 weeks.
  • Among which 24 cases only received 2 cycles of induction chemotherapy was assigned into the nonstandard chemotherapy group and 87 cases receiving 3 - 6 cycles of induction chemotherapy the standard chemotherapy group.
  • The number of preoperative chemotherapeutical cycles of standard chemotherapy group depended on the clinical and radiographic evaluation of chemotherapy efficacy.
  • RESULTS: The median follow-up time was 28 (8 - 48) months.
  • The rate of extremity preservation surgery was 89.53% (77/86) in the standard chemotherapy group and 37.5% (9/24) in the nonstandard chemotherapy group.
  • CONCLUSION: Standard intraarterial neo-adjuvant chemotherapy is more effective than nonstandard intraarterial induction chemotherapy to treat stage IIB extremity osteosarcoma.
  • [MeSH-major] Catheters, Indwelling. Chemotherapy, Adjuvant. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Brachial Artery. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Extremities. Female. Femoral Artery. Humans. Iliac Artery. Male. Subclavian Artery. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137649.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin
  •  go-up   go-down


65. García-Fernández R, Hernández-Hernández DM, Iwasaki-Otake L, Mantilla-Morales A, Ortiz-Rodríguez L, Pichardo-Romero P, Lira-Puerto V: [Scintigraphy with 99mTc-MIBI for assessment of tumor response to preoperative chemotherapy in patients with osteosarcoma]. Rev Invest Clin; 2001 Jul-Aug;53(4):324-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Scintigraphy with 99mTc-MIBI for assessment of tumor response to preoperative chemotherapy in patients with osteosarcoma].
  • [Transliterated title] Centelleografía con 99mTc MIBI para valorar la respuesta tumoral a la quimioterapia preoperatoria en pacientes con osteosarcoma.
  • In osteogenic sarcoma an increase in patient survival has been observed due to improvement of diagnostic and treatment methods.
  • The objective of the investigation was to determine the usefulness of scintigraphy with 99mTc-MIBI in comparison to clinical revaluation, in order to assess tumor response (sarcoma) to chemotherapy previous to surgery.
  • Patients with histopathological osteogenic sarcoma that received chemotherapy were included, clinical and scintigraphy response was assessed previous to the surgery.
  • Likewise the sensitivity (Se) and specificity (Sp) were superior (Se and Sp = 100% vs. Se 66.6% and Sp 75%) when therapeutically responses good and null were compared.
  • We may conclude that scintigraphy with 99mTc-MIBI used to asses the response to presurgery chemotherapy in patients with osteogenic sarcoma, together with the clinical assessment, help the physician to make therapeutically decisions with more objectivity and certainly.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Osteosarcoma / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Technetium Tc 99m Sestamibi

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11599479.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


66. Chou AJ, Gorlick R: Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther; 2006 Jul;6(7):1075-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy resistance in osteosarcoma: current challenges and future directions.
  • For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s.
  • However, survival has since plateaued, despite advances in anticancer therapy.
  • In this review, the focus is on the current understanding of the mechanisms of resistance to the most commonly used agents in the treatment of osteosarcoma and the methods employed to overcome chemotherapy resistance.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Humans

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831079.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 94
  •  go-up   go-down


67. Bacci G, Lari S: Adjuvant and neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov; 2001 Oct-Dec;86(4):253-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant and neoadjuvant chemotherapy in osteosarcoma.
  • Associated chemotherapy (adjuvant or neoadjuvant) means the association of systemic pharmacological therapy to local therapy in the treatment of tumors that, although appearing to still be localized at the time of diagnosis, have a high probability of having already given systemic micrometastases.
  • The purpose of this kind of treatment is that of controlling the micrometastases present, even if they can't be documented, in many tumors.
  • The current treatment of osteosarcoma (OS) commonly makes use of these therapies.
  • There are different types of OS and they are not indicated in all associated therapies, nor do they provide the same results.
  • Based on the site on which they occur, OS may be "primary," that is, occurring on apparently normal bone (about 95% of cases) and "secondary," that instead occur on bone that is in some way already changed (as a result of radiation, infarction, Paget's disease, etc.).
  • Based on the site and on the staging, OS can be subdivided into forms of the limbs (75% of cases) and "forms of the axile skeleton" (25% of cases) and in forms that are "still localized" at the time of diagnosis (80% of cases) and in forms "with metastases that are documented at the onset (20% of cases).
  • The present review only concerns primary high-grade OS of the limbs that were not metastatic on diagnosis, representing about 60% of all OS, and it is based on the experience of the Rizzoli Orthopaedic Institute where, between 1983 and 1996, a total of 731 patients were treated by neoadjuvant chemotherapy using five different protocols that were subsequently activated (Table I).
  • [MeSH-major] Bone Neoplasms / drug therapy. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Amputation. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Multicenter Studies as Topic. Neoadjuvant Therapy. Neoplasm Metastasis. Randomized Controlled Trials as Topic. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056242.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 42
  •  go-up   go-down


68. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K: Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother; 2002 Jun;36(6):996-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy.
  • OBJECTIVE: To conduct a retrospective evaluation of tetrahydropyranyladriamycin (PIR)-based combination chemotherapy for osteosarcomas in comparison with doxorubicin (DOX)-based regimens to determine differences in response and toxicities between DOX- and PIR-containing regimens.
  • METHODS: Toxicities and response rates of the 2 anthracyclines given as combination chemotherapy were assessed in patients with osteosarcoma, with 19 patients receiving PIR-based and 11 receiving DOX-based regimens.
  • RESULTS: The survival of osteosarcoma patients treated with PIR was significantly better than that with DOX (p = 0.023) based on 2-year follow-up.
  • CONCLUSIONS: PIR-based combination chemotherapy might be a useful and safe chemotherapeutic strategy for osteosarcomas compared with DOX regimens.
  • Further assessment is necessary to confirm the safety and efficacy of this treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12022899.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


69. Lin MT, Lin KH, Lin DT, Yang RS, Wu CT, Lu MY, Hung IJ, Yang CP, Chang TT, Shu SG, Chen RL, Hsiao TC, Chang WH, Lin KS: Unstratified chemotherapy for non-metastatic osteosarcoma of the extremities in children. J Formos Med Assoc; 2003 Jun;102(6):387-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unstratified chemotherapy for non-metastatic osteosarcoma of the extremities in children.
  • BACKGROUND AND PURPOSE: The superiority of changing postoperative chemotherapy of osteosarcoma based on histological response of the primary tumor over non-tailored chemotherapy has not been confirmed.
  • This multicenter study evaluated the effectiveness of an intensive unstratified chemotherapy regimen in Taiwanese children with osteosarcoma.
  • METHODS: Fifty patients younger than 18 years of age with previously untreated non-metastatic osteosarcoma of the extremities were enrolled.
  • Patients were treated with pre- and postoperative chemotherapy, and surgery.
  • Definitive surgery was scheduled in week 7 and postoperative chemotherapy was uniform without stratification regardless of histologic response.
  • RESULTS: Chemotherapy toxicities were considerable, but manageable.
  • Treatment delay and decreased dose-intensity were common.
  • There was one treatment-related mortality.
  • Forty three patients (86%) received limb salvage surgery and 14 patients (33%) had a good histologic response to preoperative chemotherapy.
  • CONCLUSIONS: This was the first multicenter study on the treatment of osteosarcoma from Taiwan.
  • The results suggest that a non-tailored regimen may serve as an alternative treatment strategy in the management of osteosarcoma, particularly when histologic assessment of the tumor response is not available.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12923591.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


70. Bielack SS, Machatschek JN, Flege S, Jürgens H: Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother; 2004 Jun;5(6):1243-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delaying surgery with chemotherapy for osteosarcoma of the extremities.
  • Osteosarcoma is the most frequent primary cancer of bone.
  • This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen.
  • Today, two-thirds of patients with localised extremity primaries can achieve long-term survival with such intensive multimodal therapy.
  • This article provides a summary overview of current pharmacotherapy in osteosarcoma of the extremities, focussing on the approach of preoperative 'neoadjuvant' chemotherapy and thus, the potential benefits and pitfalls of delaying surgery.
  • Prospective, multi-institutional trials are essential in guaranteeing that as many patients as possible can benefit from modern, efficacious interdisciplinary therapeutic regimens and that further progress can be made.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Extremities. Humans. Neoadjuvant Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15163270.001).
  • [ISSN] 1465-6566
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 137
  •  go-up   go-down


71. Schuetze SM: Chemotherapy in the management of osteosarcoma and Ewing's sarcoma. J Natl Compr Canc Netw; 2007 Apr;5(4):449-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.
  • Sarcomas of bone are rare malignancies diagnosed in fewer than 3000 individuals yearly in the United States.
  • Ewing's sarcoma and most osteosarcoma are high-grade neoplasms and account for approximately one half of bone sarcoma cases.
  • Fewer than 20% of patients presenting with localized Ewing's sarcoma or osteosarcoma are cured with surgery alone.
  • Modern multidisciplinary management of Ewing's sarcoma and osteosarcoma has improved the cure rate of patients with localized disease to more than 50%.
  • Primary chemotherapy for high-grade bone sarcomas often involves intensive, multiagent regimens, and few secondary chemotherapy options are available to treat refractory or relapsed disease.
  • Patient participation in clinical trials of novel therapies for Ewing's sarcoma and osteosarcoma should be strongly encouraged.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy. Sarcoma, Ewing / drug therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442235.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 60
  •  go-up   go-down


72. Lewis VO, Raymond K, Mirza AN, Lin P, Yasko AW: Outcome of postradiation osteosarcoma does not correlate with chemotherapy response. Clin Orthop Relat Res; 2006 Sep;450:60-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of postradiation osteosarcoma does not correlate with chemotherapy response.
  • Postradiation osteosarcoma is a rare tumor with a historically poor prognosis.
  • We ascertained the long-term outcome of patients with this disease treated in the era of contemporary chemotherapy.
  • Twenty-seven patients diagnosed with postradiation osteosarcoma and treated with chemotherapy and surgical resection from 1980-2003 were identified.
  • Demographics, anatomic location, stage, chemo- therapy, necrosis rate, recurrence and metastatic rates were recorded; Kaplan-Meier survival rates were estimated.
  • Twenty-two patients received induction chemotherapy for a mean of four cycles (range, 2-6 cycles).
  • Histologic response to chemotherapy did not correlate with survival.
  • Unlike conventional osteosarcoma, response to chemotherapy (necrosis) did not have prognostic significance.
  • Current chemotherapy regimens fail to impact survival in postradiation osteosarcoma.
  • LEVEL OF EVIDENCE: Therapeutic study, level IV (retrospective comparative study).
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / mortality. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / mortality. Osteosarcoma / drug therapy. Osteosarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16906104.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Kimura H, Tsuchiya H, Shirai T, Nishida H, Hayashi K, Takeuchi A, Ohnari I, Tomita K: Caffeine-potentiated chemotherapy for metastatic osteosarcoma. J Orthop Sci; 2009 Sep;14(5):556-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
  • BACKGROUND: The prognosis for patients with metastatic osteosarcoma is still poor despite the development of effective adjuvant and neoadjuvant chemotherapy regimens.
  • We have developed caffeine-potentiated chemotherapy for treatment of high-grade bone and soft tissue sarcomas based on the ability of caffeine to enhance the cytocidal effects of anticancer drugs.
  • We report results of caffeine-potentiated chemotherapy for patients with osteosarcoma with pulmonary metastases.
  • METHODS: We analyzed retrospectively overall survival and some prognostic factors for 41 patients with osteosarcoma/pulmonary metastases who were treated with caffeine-potentiated chemotherapy between 1990 and 2006.
  • At the time of the final follow-up, 11 patients were alive and 30 had died of disease.
  • We identified the primary tumor site, the histological response to preoperative chemotherapy, the number of pulmonary nodules at initial identification, the timing of pulmonary metastasis identification, and the existence of extrapulmonary metastasis as prognostic factors.
  • Patients with pulmonary metastasis identified after completion of treatment had the best prognosis, whereas patients with pulmonary metastases identified during treatment had the worst prognosis.
  • CONCLUSIONS: Caffeine-potentiated chemotherapy prolonged survival of patients who had osteosarcoma with pulmonary metastasis.
  • Especially, patients with pulmonary metastasis identified after completion of treatment or with a solitary pulmonary nodule had good prognoses.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Caffeine / administration & dosage. Lung Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19802667.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3G6A5W338E / Caffeine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


74. Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ: Osteosarcoma. J Am Acad Orthop Surg; 2009 Aug;17(8):515-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma.
  • Osteosarcoma, the most common bone sarcoma, affects approximately 560 children and adolescents annually in the United States.
  • Treatment typically includes preoperative chemotherapy, surgical resection, and postoperative chemotherapy.
  • Advances in chemotherapy protocols have led to a 5-year survival rate of 60% to 78%.
  • Among the goals of future treatment regimens are improved chemotherapeutic agents with higher specificity and lower toxicity.
  • [MeSH-major] Bone Neoplasms. Orthopedic Procedures / methods. Osteosarcoma
  • [MeSH-minor] Adolescent. Child. Combined Modality Therapy. Drug Therapy. Humans. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652033.001).
  • [ISSN] 1067-151X
  • [Journal-full-title] The Journal of the American Academy of Orthopaedic Surgeons
  • [ISO-abbreviation] J Am Acad Orthop Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


75. Anderson P: Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol; 2006 Jun;2(3):333-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
  • Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma.
  • It has been used in both canine and human osteosarcoma to reduce pulmonary metastases, the most common pattern of treatment failure for sarcomas.
  • L-MTP-PE has been well tolerated using the concept of biological cancer therapy during chemotherapy.
  • The use of L-MTP-PE with ifosfamide is the best studied combination with single agent chemotherapy.
  • This may represent a new treatment choice for osteosarcoma patients receiving ifosfamide.
  • Such patients include those with a poor initial histological response to primary therapy and/or metastatic disease including pulmonary metastases.
  • Since improved symptom control is possible using drug combinations that are especially effective for delayed nausea, outpatient high-dose ifosfamide chemotherapy combined with L-MTP-PE may lead to a safe and effective therapy while maintaining the patients' quality of life.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787112.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 0 / Phosphatidylethanolamines; 53678-77-6 / Acetylmuramyl-Alanyl-Isoglutamine; EQD2NNX741 / mifamurtide; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 83
  •  go-up   go-down


76. Ritter J, Bielack SS: Osteosarcoma. Ann Oncol; 2010 Oct;21 Suppl 7:vii320-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma.
  • The successful treatment of patients with osteosarcoma requires close cooperation within an experienced multidisciplinary team including pediatric or medical oncologists, surgeons, pathologists and radiologists.
  • Therefore, therapy should be performed in specialized centers able to provide access to the full spectrum of care.
  • As in other rare malignancies, treatment should be administered within prospective multicenter trials.
  • Therapy must include complete surgical removal of all detectable tumor sites as well as multiagent chemotherapy.
  • The chemotherapy regimen should include several or all of the following four drugs: doxorubicin, high-dose methotrexate with leukovorin-rescue, cisplatin and ifosfamide.
  • The choice of the postponed definitive surgical procedure should be influenced by the anatomical site of the primary tumor, its relationship to neighboring structures, such as vessels and nerves, age and growth potential of the patient, and probably also by the response of the tumor to preoperative chemotherapy.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20943636.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


77. Hamada K, Tomita Y, Inoue A, Fujimoto T, Hashimoto N, Myoui A, Yoshikawa H, Hatazawa J: Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med; 2009 Jan;23(1):89-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
  • OBJECTIVE: The objective of this study is to evaluate the utility of positron emission tomography (PET) with 2-deoxy-[(18)F] fluoro-D-glucose (FDG) in the assessment of the chemotherapy response of osteosarcoma when compared with the degree of necrosis determined histologically.
  • METHODS: Whole-body FDG-PET scan was performed on 11 patients with osteosarcoma.
  • All patients received neoadjuvant chemotherapy.
  • The tumor size changes on magnetic resonance imaging; FDG-PET standardized uptake values prior to (SUV(1)) and following (SUV(2)) chemotherapy were analyzed and correlated with response to chemotherapy as assessed using histopathology in surgically excised tumors.
  • Nine patients underwent FDG-PET scan both prior to and following neoadjuvant chemotherapy.
  • RESULTS: Histologically, five patients had a good histologic response to chemotherapy (>==90% necrosis).
  • CONCLUSIONS: FDG-PET imaging of osteosarcoma correlates positively with histologic response to neoadjuvant chemotherapy.
  • SUV(2) and SUV(2:1) could be feasible as non-invasive surrogate predictors of response in osteosarcoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Osteosarcoma / drug therapy. Osteosarcoma / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205843.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


78. Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L, Campanacci M: Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,. Clin Orthop Relat Res; 2001 May;(386):186-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
  • In 510 patients with osteosarcoma of the extremity treated at the authors' institute between March 1983 and June 1995 with different regimens of neoadjuvant chemotherapy, factors that influenced the histologic response were investigated.
  • The histologic response significantly and independently correlated with the number of drugs administered before surgery and with the histologic subtype of the tumor.
  • According to the number of drugs used, the percentage of total necrosis was 31% for a four-drug regimen, 18% for a three-drug regimen, and only 1.5% for a two-drug regimen.
  • According to the histologic type, the rates of total necrosis were 41% for telangiectatic tumors, 36% for fibroblastic tumors, 15% for osteoblastic tumors, and 3% for chondroblastic tumors.
  • The authors concluded that in neoadjuvant therapy of osteosarcoma, the histologic response to preoperative treatment, which correlates with prognosis, depends on the effectiveness of the chemotherapy regimen and on some features intrinsically inherent to the tumor.
  • These data should be considered when selecting the type of treatment (adjuvant or neoadjuvant) and the combinations of drugs to be used in preoperative treatment of patients with osteosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Osteonecrosis / pathology. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Amputation / methods. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Extremities. Female. Humans. Ifosfamide / administration & dosage. Logistic Models. Male. Methotrexate / administration & dosage. Multivariate Analysis. Preoperative Care. Prognosis. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11347833.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


79. Kajihara M, Sugawara Y, Miki H, Mochizuki T, Kidani T, Sakayama K: Tl-201 and Tc-99m HMDP scintigraphic findings in extraskeletal osteosarcoma. Clin Nucl Med; 2005 May;30(5):356-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tl-201 and Tc-99m HMDP scintigraphic findings in extraskeletal osteosarcoma.
  • Extraskeletal osteosarcoma is an extremely rare high-grade malignant soft tissue tumor, which accounts for approximately 4% of osteosarcomas and less than 1% of all soft tissue sarcomas.
  • We report a biopsy-proven case of extraskeletal osteosarcoma in which the bone and thallium scans were found to be useful in monitoring chemotherapy response.
  • The Tc-99m HMDP bone scan revealed increased extraskeletal uptake in the tumor.
  • [MeSH-major] Muscle Neoplasms / radionuclide imaging. Osteosarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Technetium Tc 99m Medronate / analogs & derivatives. Thallium
  • [MeSH-minor] Bone Neoplasms / radionuclide imaging. Humans. Male. Middle Aged. Radiopharmaceuticals. Thigh / radionuclide imaging

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALLIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THALLOUS CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827415.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; 7791-12-0 / thallium chloride; AD84R52XLF / Thallium; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


80. Delépine N, Alkallaf S, Cornille H, Markowska B, Delépine G: [Progress and stagnation in chemotherapy protocols for primary osteosarcoma]. Ann Med Interne (Paris); 2003 Feb;154(1):12-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
  • [Transliterated title] Progrès et stagnation dans la chimiothérapie des ostéosarcomes primitifs.
  • Thirty years ago, osteosarcoma of a limb meant amputation and death.
  • Two years after diagnosis, 80% of the patients died from pulmonary metastases, despite early amputation.
  • Successful cure requires adequate and early management centered on en-bloc resection by a specialized surgeon, followed by a long, expensive, and adapted chemotherapy.
  • We present data accumulated over the last 30 years on the treatment of osteosarcoma and point out the fundamental steps of this success story.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Methotrexate / therapeutic use. Osteosarcoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Humans. Multicenter Studies as Topic. Neoadjuvant Therapy. Preoperative Care. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746655.001).
  • [ISSN] 0003-410X
  • [Journal-full-title] Annales de médecine interne
  • [ISO-abbreviation] Ann Med Interne (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 99
  •  go-up   go-down


81. Bacci G, Ferrari S, Ruggieri P, Biagini R, Fabbri N, Campanacci L, Bacchini P, Longhi A, Forni C, Bertoni F: Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. Acta Orthop Scand; 2001 Apr;72(2):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.
  • Between April 1990 and December 1994, we treated 24 patients with telangiectatic osteosarcoma (TO) of the extremities with neoadjuvant chemotherapy using 2 protocols.
  • The histologic response to chemotherapy was good (90% or more tumor necrosis) in 23 patients, of whom 12 had total necrosis.
  • Comparing these results to the ones achieved in 269 contemporary patients with conventional osteosarcoma of the extremities using the same protocols for chemotherapy, we found a significantly better histologic response to chemotherapy (96% vs 68% of good histologic response; p = 0.004) and disease-free survival (83% vs 55%; p = 0.01) in the TO group.
  • We conclude that TO, once considered a lethal tumor, seems to be even more sensitive to chemotherapy than conventional osteosarcoma, and that most of these patients may be cured without amputation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Neoadjuvant Therapy. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Telangiectasis
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372948.001).
  • [ISSN] 0001-6470
  • [Journal-full-title] Acta orthopaedica Scandinavica
  • [ISO-abbreviation] Acta Orthop Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


82. Nathrath M, Kremer M, Letzel H, Remberger K, Höfler H, Ulle T: [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients]. Klin Padiatr; 2002 Jul-Aug;214(4):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients].
  • [Transliterated title] Expression von Genen mit möglicher prognostischer Bedeutung für das Ansprechen auf Chemotherapie bei Patienten mit Osteosarkom - Gene mit möglicher prognostischer Bedeutung beim Osteosarkom -
  • BACKGROUND: The prognosis of patients with osteosarcoma has considerably improved over the last 30 years, mainly due to developments in chemotherapy.
  • However, almost half of the osteosarcomas do not respond to chemotherapy.
  • Predictive markers for chemosensitivity at diagnosis are desirable.
  • PATIENTS AND METHODS: In order to investigate the potential of some chemotherapy-associated genes with respect to their predictive value for chemosensitivity, the mRNA expression of 8 genes was evaluated in the osteosarcomas of 45 patients and correlated to the histological response to neoadiuvant chemotherapy.
  • RESULTS: ERCC4, a member of the nucleotide excision repair system, showed a orrelation between expression and the histologically evaluated response to chemotherapy.
  • The expression of the other investigated genes HER-2/neu, HSP 70, GST, DHFR, BCRP, ERCC1 and Mlh1 showed no significant correlation to response to chemotherapy.
  • CONCLUSION: In our retrospective analyses, low expression of ERCC4 was shown to be related to poor response to chemotherapy.
  • [MeSH-major] Bone Neoplasms / genetics. DNA-Binding Proteins / genetics. Drug Resistance, Neoplasm / genetics. Neoadjuvant Therapy. Osteosarcoma / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Adolescent. Adult. Biopsy. Bone and Bones / pathology. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165907.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / xeroderma pigmentosum group F protein
  •  go-up   go-down


83. Kawai A, Sugihara S, Naito N, Ozaki T, Isu K, Hatae Y, Inoue H: Development of acute myeloid leukemia after chemotherapy for osteosarcoma. Clin Orthop Relat Res; 2001 Oct;(391):239-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of acute myeloid leukemia after chemotherapy for osteosarcoma.
  • The current study describes two patients with osteosarcoma who had acute myeloid leukemia develop after treatment with multiagent chemotherapy.
  • The incidence density for the chemotherapy protocol was 129.8 per 10,000 person-year of followup.
  • Karyotype analysis of 16 reported patients (including the current two patients) indicated that most leukemias after treatment of osteosarcoma correlated with the use of topoisomerase II inhibitors, such as doxorubicin.
  • The deoxyribonucleic acid-damaging activity of doxorubicin reinforced by the use of alkylating agents is highly suspected as a causative event in the development of leukemia after treatment of osteosarcoma.
  • As the next step in the development of treatment for patients with osteosarcoma, the type and intensity of treatment must be evaluated to minimize possible leukemogenic effects without compromising the potential for cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Leukemia, Myeloid / chemically induced. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11603675.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


84. Sami SH, Rafati AH, Hodjat P: Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor. Saudi Med J; 2008 Aug;29(8):1124-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor.
  • OBJECTIVE: To determine the histological response to preoperative chemotherapy of the percentage of tumor necrosis, and to assess the relationship between the histological response and the oncological result.
  • METHODS: Eighty patients with osteosarcoma were managed with preoperative and postoperative chemotherapy and operative resection at Shafa Yahyaeeyan Hospital, Tehran, Iran between 2003-2005.
  • Sections of each operative specimen were examined, and the histological response to chemotherapy was graded.
  • The histological response to preoperative chemotherapy (p=0.016) was the most important predictor of event-free survival.
  • CONCLUSION: The histological response to preoperative chemotherapy is an important clinical predictor of the result of operative treatment of osteosarcoma.
  • This indicator should be used to identify patients who are at high risk for metastasis, as such patients may be candidates for more intensive or novel therapy.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Necrosis. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18690304.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


85. Patel SJ, Lynch JW Jr, Johnson T, Carroll RR, Schumacher C, Spanier S, Scarborough M: Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol; 2002 Oct;25(5):489-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
  • The efficacy of neoadjuvant and adjuvant chemotherapy has been clearly established in the treatment of osteosarcoma; however, the most active regimen remains to be identified.
  • This prospective study evaluated the efficacy and toxicity of a dose-intense ifosfamide, doxorubicin, and cisplatin-based neoadjuvant regimen in adults with osteosarcoma.
  • Patients who demonstrated a "good response" (GR) to chemotherapy received the same combination postoperatively at a lower dose rate.
  • Neoadjuvant chemotherapy was well tolerated with moderate hematologic toxicity.
  • Intensive neoadjuvant chemotherapy is effective and moderately well tolerated in patients with de novo osteosarcoma.
  • The outcome data suggest that lack of a near complete response to preoperative chemotherapy reflects inherent biologic resistance to chemotherapy and hence a poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12393991.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


86. Zhao H, Yao Y, Wang Z, Lin F, Sun Y, Chen P: Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. J Chemother; 2010 Apr;22(2):119-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
  • This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II.
  • Osteosarcoma patients with lung metastases at relapse were given THP and then cisplatin (DDP) or ifosfamide (IFO).
  • Adverse reactions to THP chemotherapy were mainly gastrointestinal and myelosuppression.
  • The therapeutic effect of THP was correlated with the abrogated expression of pglycoprotein and/or topoisomerase-II positive expression.
  • For osteosarcoma patients with secondary lung metastasis, THP-based chemotherapy regimens are safe and effective as a salvage chemotherapy option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Doxorubicin / analogs & derivatives. Lung Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cisplatin / therapeutic use. DNA Topoisomerases, Type II / biosynthesis. Disease-Free Survival. Female. Humans. Ifosfamide / therapeutic use. Male. Middle Aged. P-Glycoprotein / biosynthesis. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20435572.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; EC 5.99.1.3 / DNA Topoisomerases, Type II; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


87. Wikström AM, Hovi L, Dunkel L, Saarinen-Pihkala UM: Restoration of ovarian function after chemotherapy for osteosarcoma. Arch Dis Child; 2003 May;88(5):428-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of ovarian function after chemotherapy for osteosarcoma.
  • AIM: To evaluate ovarian function after modern intensive multi-agent chemotherapy for osteosarcoma given during childhood or adolescence.
  • METHODS: After discontinuation of treatment, 10 female osteosarcoma survivors were followed up for 1.5-14 (median 4.6) years.
  • Their age at diagnosis was a median of 12.9 (range 6-15) years and at the last follow up 18.6 (range 16-22).
  • RESULTS: Prior to diagnosis, 5/10 had had their menarche, and one had it while on therapy.
  • At discontinuation of chemotherapy, ovarian function had severely deteriorated; none of the girls experienced regular menstrual cycles.
  • CONCLUSIONS: The modern multi-agent chemotherapy applied for osteosarcoma impairs ovarian function.
  • Normalisation of ovarian function is common, even in cases with severe hypergonadotrophic hypogonadism, but may only occur after several years off chemotherapy.
  • Regular assessment of ovarian function and cautious use of hormone replacement therapy are important in patients with chemotherapy induced gonadal damage.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy. Ovary / physiopathology
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Estradiol / analysis. Female. Follicle Stimulating Hormone / blood. Follow-Up Studies. Hormone Replacement Therapy. Humans. Menarche / physiology. Puberty / physiology. Retrospective Studies

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Suppl. 1999 Dec;88(433):1-4 [10626537.001]
  • [Cites] Endocrinol Metab Clin North Am. 1998 Dec;27(4):927-43 [9922915.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] Hum Reprod. 2001 Sep;16(9):1838-44 [11527885.001]
  • [Cites] N Engl J Med. 1973 Nov 29;289(22):1159-62 [4754963.001]
  • [Cites] Clin Chem. 1977 Jul;23(7):1250-7 [872371.001]
  • [Cites] Br J Cancer. 1978 Jul;38(1):82-7 [687521.001]
  • [Cites] Cancer Invest. 1984;2(3):181-92 [6203625.001]
  • [Cites] Cancer. 1985 May 15;55(10):2364-72 [3986739.001]
  • [Cites] N Engl J Med. 1987 Nov 19;317(21):1315-21 [3683460.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):813-8 [3130466.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):2-8 [10401490.001]
  • [Cites] Arch Dis Child. 1999 May;80(5):452-4 [10208952.001]
  • [Cites] Med Pediatr Oncol. 1989;17(5):409-13 [2507885.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jan;70(1):107-14 [2104623.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):6-12 [1727214.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):411-5 [9010116.001]
  • [Cites] J Pediatr. 1997 Feb;130(2):210-6 [9042122.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Feb;46(2):217-9 [9135705.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1961-5 [11064353.001]
  • (PMID = 12716717.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  • [Other-IDs] NLM/ PMC1719556
  •  go-up   go-down


88. Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL: Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer; 2009 Jun 1;115(11):2514-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma.
  • BACKGROUND: Samarium-153 ethylenediaminetetramethylene phosphonic acid ((153)Sm-EDTMP) has been used to treat patients with high-risk osteosarcoma.
  • METHODS: Patients with recurrent or refractory osteosarcoma with bone metastases were enrolled in this study.
  • Complete blood counts were monitored weekly, and the primary DLT was defined as failure to achieve an absolute neutrophil count >750/mm(3) and a platelet count >75,000/mm(3) within 6 weeks of treatment.
  • Grade 2 and 3 pulmonary toxicity (graded according to the National Cancer Institute Common Toxicity Criteria [version 3.0]) as reported in 2 patients (at administered activities of 44.8 MBq/kg and 51.8 MBq/kg) was attributable to progressive pulmonary disease.
  • CONCLUSIONS: Patients with osteosarcoma who have previously been heavily treated with chemotherapy can be safely administered (153)Sm-EDTMP with rapid hematologic recovery.
  • The data from the current study support the development of a future trial to assess the efficacy of combining targeted radiotherapy with cytotoxic chemotherapy as a treatment option for patients with high-risk osteosarcoma.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):189-96 [11773169.001]
  • [Cites] Mayo Clin Proc. 2003 Feb;78(2):147-55 [12583525.001]
  • [Cites] Cancer. 1972 Aug;30(2):393-400 [4506001.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Biometrics. 1990 Mar;46(1):33-48 [2350571.001]
  • [Cites] Stat Med. 1995 Jun 15;14(11):1149-61 [7667557.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1517-27 [18020921.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1954 Nov;72(5):813-8 [13207496.001]
  • [Cites] Br J Surg. 1964 Apr;51:252-74 [14138245.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1023-7 [15937315.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6895-900 [16203780.001]
  • [Cites] Clin Trials. 2006;3(1):57-71 [16539090.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):37S-61S [10025848.001]
  • (PMID = 19338063.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116477-03; United States / NCI NIH HHS / CA / R01 CA116477; United States / NCI NIH HHS / CA / R01 CA116477-03
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate
  • [Other-IDs] NLM/ NIHMS246423; NLM/ PMC2974628
  •  go-up   go-down


89. Yonemoto T, Ishii T, Takeuchi Y, Hagiwara Y, Iwata S, Tatezaki S: Recently intensified chemotherapy for high-grade osteosarcoma may affect fertility in long-term male survivors. Anticancer Res; 2009 Feb;29(2):763-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recently intensified chemotherapy for high-grade osteosarcoma may affect fertility in long-term male survivors.
  • AIM: To investigate the marital status and fertility in long-term survivors of high-grade osteosarcoma.
  • PATIENTS AND METHODS: We surveyed the marital rate (number of married persons/total number of persons) in 46 long-term survivors of osteosarcoma who were treated in our hospital between 1976 and 2002.
  • The participants were divided into 2 groups: one group (MC) in which moderate-dose chemotherapy was performed between 1976 and 1986; and another group (IC) in which intensive-dose chemotherapy was performed between 1987 and 2002.
  • CONCLUSION: These results suggest that recently intensified chemotherapy for osteosarcoma affects fertility in long-term male survivors.
  • [MeSH-major] Bone Neoplasms / drug therapy. Fertility. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331233.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


90. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, Zielenska M: Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer; 2010;10:202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
  • BACKGROUND: Human osteosarcoma is the most common pediatric bone tumor.
  • There is limited understanding of the molecular mechanisms underlying osteosarcoma oncogenesis, and a lack of good diagnostic as well as prognostic clinical markers for this disease.
  • METHODS: Our objective was to assess relative expression levels of these 16 genes as potential biomarkers of osteosarcoma oncogenesis and chemotherapy response in human tumors.
  • We performed quantitative expression analysis in a panel of 22 human osteosarcoma tumors with differential response to chemotherapy, and 5 normal human osteoblasts.
  • In addition to being overexpressed in osteosarcoma tumor samples relative to normal osteoblasts, RUNX2 was the only gene of the 16 to show significant overexpression in tumors that had a poor response to chemotherapy relative to good responders.
  • CONCLUSION: These data underscore the loss of tumor suppressive pathways and activation of specific oncogenic mechanisms associated with osteosarcoma oncogenesis, while drawing attention to the role of RUNX2 expression as a potential biomarker of chemotherapy failure in osteosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / genetics. Bone Neoplasms / drug therapy. Bone Neoplasms / genetics. Core Binding Factor Alpha 1 Subunit / genetics. Osteosarcoma / drug therapy. Osteosarcoma / genetics
  • [MeSH-minor] Adolescent. Biopsy. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. RNA, Messenger / analysis. Retrospective Studies. Treatment Failure. Up-Regulation

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):40-52 [11953594.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Pediatr Dev Pathol. 2003 Jan-Feb;6(1):43-53 [12375129.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):1-30 [12885459.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Nov;38(3):215-25 [14506695.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2004;14(1-2):1-41 [15104525.001]
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):77-82 [15305059.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):158-64 [15350306.001]
  • [Cites] Cancer. 1982 Mar 15;49(6):1221-30 [6174200.001]
  • [Cites] J Cell Biochem. 2008 Nov 1;105(4):965-70 [18821584.001]
  • [Cites] Mol Diagn Ther. 2008;12(6):359-74 [19035623.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23):2502-4 [19052138.001]
  • [Cites] Endocrine. 2009 Feb;35(1):101-11 [19020999.001]
  • [Cites] Neoplasia. 2009 Mar;11(3):260-8, 3p following 268 [19242607.001]
  • [Cites] Hum Mol Genet. 2009 Jun 1;18(11):1962-75 [19286668.001]
  • [Cites] BMC Cancer. 2009;9:150 [19445706.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Aug;48(8):679-93 [19441093.001]
  • [Cites] Hum Mol Genet. 2009 Dec 15;18(24):4818-29 [19776030.001]
  • [Cites] Br J Cancer. 2009 Dec 15;101(12):2064 [19997114.001]
  • [Cites] J Clin Epidemiol. 2001 Apr;54(4):343-9 [11297884.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2181-9 [11596036.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 1990 Jul;5(7):989-1000 [2115647.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7950-4 [2253237.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2699-705 [7989947.001]
  • [Cites] Gen Diagn Pathol. 1996 Jun;142(1):25-32 [8793483.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):556-63 [9778623.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):392-403 [15660435.001]
  • [Cites] Apoptosis. 2005 Mar;10(2):267-75 [15843888.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2195-201 [16489021.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1387-98 [16939397.001]
  • [Cites] BMC Cancer. 2006;6:237 [17022822.001]
  • [Cites] Curr Mol Med. 2006 Nov;6(7):809-17 [17100605.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2313-7 [17438088.001]
  • [Cites] Dev Dyn. 2007 Jul;236(7):1876-90 [17497678.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Nov;179(1):52-61 [17981215.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36240-9 [17956871.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7795-802 [18829534.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1264-77 [18838962.001]
  • [Cites] Yale J Biol Med. 2007 Dec;80(4):165-78 [18449388.001]
  • [Cites] Genes Dev. 2008 Jun 15;22(12):1662-76 [18559481.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):937-46 [18567798.001]
  • [Cites] J Neurosci Res. 2008 Aug 15;86(11):2450-61 [18438928.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2114-30 [18563507.001]
  • [Cites] PLoS One. 2008;3(7):e2834 [18698372.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):435-45 [18679706.001]
  • [Cites] Rev Recent Clin Trials. 2008 Sep;3(3):228-31 [18782081.001]
  • [Cites] Mol Pathol. 2002 Dec;55(6):389-93 [12456778.001]
  • (PMID = 20465837.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Core Binding Factor Alpha 1 Subunit; 0 / RNA, Messenger; 0 / RUNX2 protein, human
  • [Other-IDs] NLM/ PMC2875220
  •  go-up   go-down


91. Bacci G, Longhi A, Forni C, Fabbri N, Briccoli A, Barbieri E, Mercuri M, Balladelli A, Ferrari S, Picci P: Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):505-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
  • PURPOSE: Evaluate treatment and outcome of 20 patients with radioinduced osteosarcoma (RIO).
  • Because of previous primary tumor treatment, RIO protocols were different from others we used for non-RIO.
  • PATIENTS AND METHODS: Between 1983 and 1998, we treated 20 RIO patients, ages 4-36 years (mean 16 years), with chemotherapy (two cycles before surgery, three postoperatively).
  • The three postoperative treatments were performed with cycles of MTX/CDP; IFO was used as single agent per cycle repeated three times.
  • RESULTS: Two patients received palliative treatment because their osteosarcoma remained unresectable after preoperative chemotherapy.
  • The remaining 18 patients had surgery (7 amputations, 11 resections); histologic response to preoperative chemotherapy was good in 8 patients, poor in 10.
  • At a mean follow-up of 11 years (range, 7-22 years), 9 patients remained continuously disease-free, 10 died from osteosarcoma and 1 died from a third neoplasm (myeloid acute leukemia).
  • These results are not significantly different from those achieved in 754 patients with conventional osteosarcoma treated in the same period with protocols used for conventional treatment.
  • However, this later group had an 18% 3-year event-free survival after treatment of relapse vs. 0% in the RIO group.
  • CONCLUSION: Treated with neoadjuvant chemotherapy RIO seem to have an outcome that is not significantly different from that of comparable patients with conventional primary high grade osteosarcoma (5-year event-free survival: 40% vs. 60%, p = NS; 5-year overall survival 40% vs. 67%, p < 0.01).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Neoadjuvant Therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118571.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


92. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev; 2006 Oct;32(6):423-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone osteosarcoma in the pediatric age: state of the art.
  • The current combination treatment, chemotherapy and surgery, has significantly improved the cure rate and the survival rate of primary bone osteosarcoma.
  • Even in patients with poor prognosis, such as those with metastases at diagnosis, the 5-year survival rate has reached 20-30% due to chemotherapy and the surgical removal of metastases and primary tumor.
  • However, the most effective drugs are still the same as those employed over the last 20 years as front line neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide.
  • No standard, second line therapy exists for those who relapse.
  • At relapse, due to the lack of new non-cross-resistant drugs, surgery is still the main option when feasible.
  • Other drugs have been employed in relapsed patients with poor results.
  • This article reviews the state of the art of treatment for bone osteosarcoma in the pediatric age.
  • [MeSH-major] Bone Neoplasms. Osteosarcoma
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Male. Neoadjuvant Therapy. Prognosis. Survival Rate


93. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, Furuse K, Minamizaki T, Kawaguchi N, Yamawaki S: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci; 2009 Jul;14(4):397-404
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
  • BACKGROUND: Osteosarcoma is the most frequent primary malignant bone tumor.
  • In Europe and the United States, its prognosis has been greatly improved by the use of multimodal treatment, including preoperative and postoperative chemotherapy as well as surgery.
  • In Japan, however, only a few clinical studies on osteosarcoma have been carried out.
  • METHODS: To evaluate the efficacy of neoadjuvant chemotherapy on nonmetastatic, operable osteosarcoma arising in the extremities, a prospective multi-institutional phase II trial, the Neoadjuvant Chemotherapy for Osteosarcoma (NECO) study, was conducted.
  • Preoperative chemotherapy included high-dose methotrexate (HD-MTX), cisplatin (CDDP), and adriamycin (ADR).
  • If the induction therapy was assessed as not effective, high-dose ifosfamide (IFO) was added to the chemotherapy regimen.
  • A good histological response to the induction chemotherapy resulted in favorable OAS (78.7%).
  • The patients assessed as poor histological responders with progressive disease after the induction chemotherapy exhibited comparable outcomes (OAS 89.5%, EFS 68.2%).
  • There were no significant differences between the OAS and EFS rates of the patients in terms of response to preoperative chemotherapy.
  • CONCLUSIONS: We analyzed the results of the intensive neoadjuvant chemotherapy and the effects of adding IFO on patients with osteosarcoma in Japan.
  • The results suggest efficacy of the high-dose IFO addition to the standard three-drug chemotherapy regimen.
  • However, a randomized clinical study is needed to establish the true impact of IFO on patients with osteosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Neoadjuvant Therapy / methods. Neoplasm Invasiveness / pathology. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Japan. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Neoplasm Staging. Preoperative Care / methods. Prospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662473.001).
  • [ISSN] 1436-2023
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


94. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, Balladelli A, Pratelli L, Bacci G: Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother; 2009 Apr;21(2):205-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
  • The influence of age and sex on chemotherapy-related toxicity was evaluated in children and adults with non metastatic osteosarcoma. treatment consisted of methotrexate (MTX, 12 g/m(2)), cisplatin (CDP 120 mg/m(2)) and doxorubicin (ADM 75-90 mg/m(2)) and high-dose ifosfamide (HDIFO).
  • Adults (up to 40 years) can be treated with pediatric protocols for osteosarcoma and they experience lower hematologic toxicity compared to pediatric population. further investigations on sex-related susceptibility to chemotherapy in osteosarcoma patients are recommended.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423475.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


95. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer; 2005 Dec;41(18):2836-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.
  • Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different protocols of neoadjuvant chemotherapy.
  • The 10-year EFS and OS were 52% and 57%, respectively, and the results significantly correlated with serum alkaline phosphatase levels; the type of chemotherapy (adjuvant vs neoadjuvant); and with histologic response to pre-operative treatment.
  • Aggressive chemotherapy and surgery could cure about the 60% of patients with osteosarcoma of the extremity.
  • However, since local or systemic relapses, myocardiopathies and a second malignancy are possible even 5 or more years since the beginning of treatment, a long-term follow-up is recommended.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary / drug therapy. Postoperative Complications / etiology. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298125.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


96. Bacci G, Balladelli A, Palmerini E, Alberghini M, Pollastri P, Galletti S, Mercuri M, Picci P: Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J Pediatr Hematol Oncol; 2008 Dec;30(12):908-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience.
  • Medical records of 133 patients, 10 years old or younger with primary high-grade nonmetastatic osteosarcoma of the extremities treated at the Rizzoli Institute between 1983 and 1999 with neoadjuvant chemotherapy were reviewed and compared with those of 782 patients aged 11 to 40 years treated in the same period with the same chemotherapy protocols.
  • The authors conclude that there does not seem to be any indication to treat preadolescent primary high-grade nonmetastatic osteosarcoma patients by alternative and/or more aggressive therapies.
  • [MeSH-major] Bone Neoplasms / drug therapy. Neoadjuvant Therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Extremities / pathology. Extremities / surgery. Female. Follow-Up Studies. Humans. Limb Salvage. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131777.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Longhi A, Fabbri N, Donati D, Capanna R, Briccoli A, Biagini R, Bernini G, Ferrari S, Versari M, Bacci G: Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother; 2001 Jun;13(3):324-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases.
  • Between January 1995 and December 1999, 11 patients with synchronous multifocal osteosarcoma (SMO) received neoadjuvant treatment with high-dose methotrexate, cisplatinum, Adriamycin, and ifosfamide.
  • After primary chemotherapy in 4 patients who had only two bone localizations, it was possible to treat all tumor foci locally.
  • The remaining patients, with more than three bones involved, were treated surgically only in 3 cases at the primary site, while secondary lesions did not receive any treatment.
  • All patients died of the tumor 6 to 24 months after the beginning of treatment (mean 11.9 months).
  • Nevertheless, the survival time of the 4 patients with locally treated lesions was significantly longer than the one of 7 patients in whom the secondary lesions were not locally treated (18.2 vs 9.1 months; P<0.008).
  • It should be noted that those patients simultaneously operated on two sites, the response to chemotherapy of "primary" and "secondary" lesions was always similar.
  • This homogeneity supports the thesis that in synchronous multifocal osteosarcoma the tumors are not multicentric in origin but represent bone-to-bone metastases from a monocentric tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neoadjuvant Therapy. Neoplasms, Multiple Primary / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450892.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


98. Guo W, Tang XD, Liu J, Yang Y: [Evaluation of neoadjuvant chemotherapy for patients with stage II osteosarcoma]. Zhonghua Wai Ke Za Zhi; 2009 Nov 1;47(21):1634-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemotherapy for patients with stage II osteosarcoma].
  • OBJECTIVE: To retrospectively review the effect of chemotherapy and survival rate of osteosarcoma in extremity.
  • METHODS: Between July 1997 and July 2007, 296 patients with osteosarcoma received neo-adjuvant chemotherapy and surgery.
  • The tumors located in proximal femur in 10 patients, diaphyseal of femur in 7, distal femur in 148, proximal tibia in 80, distal tibia in 5, fibula in 11, humerus in 33, and distal radius in 2 patients.
  • All patients received evaluation of preoperative chemotherapy, and 72 patients had analysis of tumor necrosis after operation.
  • RESULTS: After mean follow-up of 47 months, metastasis developed in 98 (33.1%) patients.
  • The metastatic rate was 15.5%, 31.0%, and 77.1% in patients with substantial effective chemotherapy, partial effective chemotherapy, and no effective chemotherapy, respectively.
  • In tumor necrosis analysis, reduction of tumor volume and more clear margin after preoperative chemotherapy were related to higher tumor necrosis.
  • CONCLUSIONS: The patients with osteosarcoma should receive chemotherapy as soon as possible.
  • More effective chemotherapy means lower metastatic rate and higher no event survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Extremities. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137398.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Longhi A, Pasini E, Bertoni F, Pignotti E, Ferrari C, Bacci G: Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy. J Chemother; 2004 Dec;16(6):582-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twenty-year follow-up of osteosarcoma of the extremity treated with adjuvant chemotherapy.
  • We have updated the results of an adjuvant chemotherapy study of 106 patients with osteosarcoma of the extremities published 17 years ago, treated by surgery followed by adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX) and doxorubicin (ADM), between 1980-1983, and followed-up for at least 20 years (20-23 years).
  • We conclude that osteosarcoma patients treated with chemotherapy are at risk of late adverse events.
  • Protracted medical follow-up and long-term updated results are useful to identify, at an early stage, late relapses and late treatment-related complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Morbidity. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700851.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


100. Rossi B, Schinzari G, Maccauro G, Scaramuzzo L, Signorelli D, Rosa MA, Fabbriciani C, Carlo B: Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord; 2010;11:34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
  • BACKGROUND: Angiogenesis plays a role in the progression of osteosarcoma, as well as in other mesenchymal tumors and carcinomas, and it is most commonly assessed by vascular endothelial growth factor (VEGF) expression or tumor CD31-positive microvessel density (MVD).
  • Tumor VEGF expression is predictive of poor prognosis, and chemotherapy can affect the selection of angiogenic pattern.
  • The aim of the study was to investigate the clinical and prognostic significance of VEGF and CD31 in osteosarcoma, both at diagnosis and after neoadjuvant chemotherapy, in order to identify a potential role of chemotherapy in angiogenic phenotype.
  • METHODS: A retrospective analysis was performed on 16 patients with high grade osteosarcoma.
  • In each case archival pre-treatment biopsy tissue and post-chemotherapy tumor specimens were immunohistochemically stained against CD31 and VEGF, as markers of angiogenic proliferation both in newly diagnosed primary osteosarcoma and after multidrug chemotherapy including high-dose methotrexate (HDMTX).
  • RESULTS: Expression of VEGF was positive in 11 cases/16 of cases at diagnosis.
  • VEGF expression in viable tumor cells after neoadjuvant chemotherapy was observed in all cases; in particular, there was an increased VEGF expression (post-chemotherapy VEGF--biopsy VEGF) in 11 cases/16.
  • CD31 expression increased in 11 cases/16 and decreased in 3 cases after chemotherapy.
  • The data relating to the change in staining following chemotherapy appear statistically significant for VEGF expression (p < 0.05), but not for CD31 (p > 0.05).
  • CONCLUSIONS: Even if the study included few patients, these results confirm that VEGF and CD31 expression is affected by multidrug chemotherapy including HDMTX.
  • The expression of angiogenic factors that increase microvessel density (MVD) can contribute to the penetration of chemotherapeutic drugs into the tumor in the adjuvant stage of treatment.
  • So VEGF could have a paradoxical effect: it is associated with a poor outcome but it could be a potential target for anti-angiogenic therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bone Neoplasms / drug therapy. Methotrexate / administration & dosage. Osteosarcoma / drug therapy. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD31 / metabolism. Biomarkers / metabolism. Disease-Free Survival. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Predictive Value of Tests. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Mar 1;109(5):813-9 [17265525.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1250-7 [18349828.001]
  • [Cites] Clin Orthop Relat Res. 2008 Sep;466(9):2052-9 [18528739.001]
  • [Cites] Onkologie. 2008 Oct;31(10):535-40 [18854653.001]
  • [Cites] Prilozi. 2008 Dec;29(2):309-23 [19259055.001]
  • [Cites] J Bone Joint Surg Br. 2009 Jun;91(6):784-8 [19483233.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):1035-9 [19621435.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1089-93 [10533453.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):341-6 [10746677.001]
  • [Cites] Clin Orthop Relat Res. 2001 May;(386):186-96 [11347833.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):864-9 [11953816.001]
  • [Cites] Clin Orthop Relat Res. 2003 Feb;(407):159-66 [12567143.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Bone Joint Surg Br. 2004 Jan;86(1):143-7 [14765882.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1515-21 [3861228.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] Oncology. 1996 May-Jun;53(3):221-7 [8643225.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):206-13 [9010092.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1379-84 [9823983.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8531-7 [15623635.001]
  • [Cites] Mod Pathol. 2006 May;19(5):738-45 [16528367.001]
  • [Cites] Clin Orthop Relat Res. 2006 Jul;448:193-8 [16826116.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Sep;14(3):334-40 [16932026.001]
  • [Cites] Curr Treat Options Oncol. 2006 Nov;7(6):444-55 [17032557.001]
  • (PMID = 20158913.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2835659
  •  go-up   go-down






Advertisement